Azithromycin (All Populations Monograph)

Indications/Dosage
expand all | collapse all

Labeled

- bacterial conjunctivitis
- bronchitis
- chancroid
- chlamydial infection
- community-acquired pneumonia
- gonorrhea
- Mycobacterium avium complex (MAC) prophylaxis
- Mycobacterium avium complex infection
- non-gonococcal urethritis (NGU)
- otitis media
- pelvic inflammatory disease (PID)
- pharyngitis
- pneumonia
- sinusitis
- skin and skin structure infections
- tonsillitis

Off-Label, Recommended

- babesiosis †
- bartonellosis †
- bartonellosis prophylaxis †
- campylobacteriosis †
- chlamydial infection prophylaxis †
- choledocholithiasis †
- coronavirus disease 2019 (COVID-19) †
- cystic fibrosis †
- dental abscess (apical) †
- dental abscess (periapical) †
- dental infection †
- dentoalveolar infection †
- endocarditis prophylaxis †
- gonorrhea prophylaxis †
- granuloma inguinale †
- Lyme disease †
- lymphogranuloma venereum †
- ophthalmia neonatorum †
- pertussis (whooping cough) †
- pertussis prophylaxis †
- rheumatic fever prophylaxis †
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection †
- shigellosis †
- syphilis †
- traveler's diarrhea †
- typhoid fever †

† Off-label indication

Per the manufacturer, this drug has been shown to be active against most strains of the following microorganisms either in vitro and/or in clinical infections:

Bacteroides bivius, Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, CDC coryneform group G, Chlamydia trachomatis, Chlamyphila pneumoniae, Clostridium perfringens, Haemophilus ducreyi, Haemophilus influenzae (beta-lactamase negative), Haemophilus influenzae (beta-lactamase positive), Legionella pneumophila, Moraxella catarrhalis, Mycobacterium avium, Mycobacterium intracellulare, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Peptostreptococcus sp., Prevotella bivia, Staphylococcus aureus (MSSA), Streptococcus agalactiae (group B streptococci), Streptococcus mitis, Streptococcus pneumoniae, Streptococcus pyogenes (group A beta-hemolytic streptococci), Streptococcus sp., Treponema pallidum, Ureaplasma urealyticum, Viridans streptococci.
NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not been established in adequate and well-controlled clinical trials.

This drug may also have activity against the following microorganisms:

*Bacillus anthracis, Gardnerella vaginalis, Helicobacter pylori, Klebsiella granulomatis, Mycoplasma genitalium, Rickettsia tsutsugamushi, Salmonella typhi, Staphylococcus epidermidis, Streptococcus sp. (Group C), Streptococcus sp. (Group F), Streptococcus sp. (Group G), Toxoplasma gondii, Vibrio cholerae.*

NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this list does not necessarily negate the drug’s activity against the organism.

Azithromycin is used for many indications. In an effort to present the data that is most relevant to the management of COVID-19, only dosing related to community-acquired pneumonia and COVID-19 are included in this document.

INVESTIGATIONAL USE: For adjunctive use in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the virus that causes coronavirus disease 2019 (COVID-19)†

**Oral dosage (immediate-release)**

- **Adults**
  
  Data are limited and efficacy has not been established. Azithromycin is being used in some COVID-19 institutional protocols. Risk of adverse events (e.g., cardiac arrhythmias), must be weighed against potential benefit. 500 mg PO on day 1 then 250 mg PO once daily for 5 days was administered in combination with hydroxychloroquine in a small study. On day 6, all patients treated with hydroxychloroquine and azithromycin (n = 6) were virologically cured compared to 57.1% of patients treated with hydroxychloroquine alone (n = 20). [65147] Another small study (n = 11) reviewed the same azithromycin plus hydroxychloroquine regimen and found nasopharyngeal swabs were still positive for SARS-CoV-2 in 8 of 10 patients at 5 to 6 days after treatment initiation.[65198] In a retrospective analysis of a multicenter cohort study (n = 349) in patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), 136 patients received macrolide therapy in combination with antiviral treatment. Macrolide therapy was not associated with a reduction in 90-day mortality compared to the control group (adjusted OR: 0.84; 95% CI: 0.47 to 1.51; p = 0.56).[65149]

For the treatment of community-acquired pneumonia (CAP)

**Oral dosage (immediate-release)**

- **Outpatient Adults**
  
  500 mg PO on day 1, followed by 250 mg PO once daily for at least 5 days as monotherapy for patients without comorbidities or risk factors for MRSA or *P. aeruginosa* and as part of combination therapy for patients with
comorbidities. Guide treatment duration by clinical stability. FDA-approved labeling recommends a 5-day treatment course.

- **Hospitalized Adults**

  500 mg PO once daily for at least 5 days as part of combination therapy. Guide treatment duration by clinical stability.

- **Adolescents**

  10 mg/kg/dose (Max: 500 mg/dose) PO for 1 day, followed by 5 mg/kg/dose (Max: 250 mg/dose) PO once daily for 4 days. Guidelines recommend azithromycin as oral step-down therapy or as initial oral therapy in patients with atypical pathogens and as part of combination therapy for hospitalized HIV-infected patients.

- **Infants and Children 6 months to 12 years**

  10 mg/kg/dose (Max: 500 mg/dose) PO for 1 day, followed by 5 mg/kg/dose (Max: 250 mg/dose) PO once daily for 4 days. Guidelines recommend azithromycin as oral step-down therapy or as initial oral therapy in patients with atypical pathogens and as part of combination therapy for hospitalized HIV-infected patients.

- **Infants 3 to 5 months†**

  10 mg/kg/dose PO for 1 day, followed by 5 mg/kg/dose PO once daily for 4 days. Guidelines recommend azithromycin as oral step-down therapy or as initial oral therapy in patients with atypical pathogens and as part of combination therapy for hospitalized HIV-infected patients.

**Oral dosage (extended-release)**

- **Adults**

  2 g PO as a single dose. This dosage form is not recommended for patients with moderate or severe illness or those with other underlying risk factors for which oral therapy is inappropriate.

- **Infants, Children, and Adolescents 6 months to 17 years**

  60 mg/kg/dose (Max: 2 g/dose) PO as a single dose. This dosage form is not recommended for patients with moderate or severe illness or those with other underlying risk factors for which oral therapy is inappropriate.

**Intravenous dosage**

- **Adults**

  500 mg IV once daily for at least 5 days as part of combination therapy for hospitalized patients. Guide treatment duration by clinical stability. FDA-approved labeling recommends IV therapy for at least 2 days then step-down to oral therapy to complete a 7- to 10-day treatment course. The switch to oral therapy should be done at the discretion of the physician and based on the clinical response of the patient.
500 mg IV once daily for at least 2 days, followed by oral therapy to complete a 7- to 10-day treatment course. Guidelines recommend azithromycin as monotherapy for definitive atypical pneumonia and as part of combination therapy for hospitalized patients, including HIV-infected patients, when atypical pathogens are suspected.[34362] [46963]

- **Infants, Children, and Adolescents 3 months to 15 years†**

10 mg/kg/dose (Max: 500 mg/dose) IV once daily for 2 days, followed by oral therapy to complete a 5-day treatment course. Guidelines recommend azithromycin as monotherapy for definitive atypical pneumonia and as part of combination therapy for hospitalized patients, including HIV-infected patients, when atypical pathogens are suspected.[34361] [34362] [46963]

---

**Therapeutic Drug Monitoring**

The following recommendations are for baseline and continuous monitoring when using azithromycin with hydroxychloroquine or chloroquine:

- Obtain a pre-treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG device.
- Obtain baseline electrolytes, including calcium, magnesium, and potassium; correct abnormalities.
- Determine if the patient is currently on any QT-prolonging medications that can be discontinued.[65170]
- Document high-risk cardiovascular and comorbid conditions.[65170] Assess and adjust for hepatic and renal dysfunction.[65242]

**Inpatient Use**

- Place telemetry prior to initiation, if possible.
- Monitor and optimize serum electrolytes daily.[65242]
- If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging medications, and proceed with close QTc surveillance.[65170] Some experts recommend withholding treatment for patients with a baseline QTc of 500 msec or more (or more than 530 to 550 msec in patients with a QRS interval more than 120 msec) or in those with congenital long QT syndrome.[65242]
- If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal males), or 480 to 499 msec (postpubertal females), correct contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging medications, and obtain an initial on-therapy QTc daily (or 48 and 96 hours after treatment initiation).[65170] [65242]
- If the baseline QTc is less than 460 msec (prepubertal), less than 470 msec (postpubertal males), or less than 480 msec (postpubertal females), correct electrolyte abnormalities and obtain an initial on-therapy QTc daily (48 and 96 hours after treatment initiation).[65170] [65242]
- Obtain an initial on-therapy QTc approximately 2 to 4 hours after the first dose and then daily (some recommend 48 and 96 hours after treatment initiation).[65170] [65242]
- Discontinue azithromycin and/or reduce the antimalarial dose if the subsequent QTc is prolonged or significantly increased above the specified parameters. If the QTc remains prolonged or significantly increased, reevaluate the risk/benefit of therapy, consider consultation with an electrophysiologist, and consider hydroxychloroquine/chloroquine discontinuation.[65242]
Outpatient Use

- Do not initiate outpatient therapy in the setting of acute renal or hepatic failure.[65242]
- If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging medications, and proceed with close QTc surveillance.[65170] Some experts recommend withholding treatment in patients with a baseline QTc of 480 msec or more (or more than 510 to 530 msec in patients with a QRS interval more than 120 msec), congenital long QT syndrome, or a Tisdale risk score of 11 or more.[65242]
- Consider no further ECG/telemetry assessment for patients with a Tisdale risk score of 6 or less, if resource or quarantine constraints are prohibitive of monitoring. Otherwise, repeat the ECT 2 to 3 hours after dosing on day 3 of therapy. If the QTc exceeds 500 msec (or 530 to 550 msec if QRS is more than 120 msec) or increases by more than 30 to 60 msec, consider discontinuing therapy.[65242]

Maximum Dosage Limits

- Adults

500 mg/day PO is FDA-approved dosage; however, doses up to 1,200 mg/day PO are used off-label; 2 g PO when given as single dose; 500 mg/day IV infusion.

- Geriatric

500 mg/day PO is FDA-approved dosage; however, doses up to 1,200 mg/day PO are used off-label; 2 g PO when given as single dose; 500 mg/day IV infusion.

- Adolescents

16 to 17 years: 500 mg/day PO is FDA-approved dosage; however, doses up to 1,200 mg/day PO are used off-label; 2 g PO when given as single dose; 500 mg/day IV infusion.

13 to 15 years: For the immediate-release oral suspension or tablets, 12 mg/kg/day PO (Max: 500 mg/dose) and single doses up to 30 mg/kg PO (Max: 1.5 g/dose) are the maximum FDA-approved dosages; however, doses up to 20 mg/kg/day PO (Max: 1,000 mg/day) or 1,200 mg/day are used off-label. For extended-release oral suspension, 60 mg/kg single dose PO (Max: 2 g/dose). Safety and efficacy have not been established for IV; however, doses up to 10 mg/kg/day (Max: 500 mg/dose) have been used off-label.

- Children

2 to 12 years: For the immediate-release oral suspension or tablets, 12 mg/kg/day PO (Max: 500 mg/dose) and single doses up to 30 mg/kg PO (Max: 1.5 g/dose) are the maximum FDA-approved dosages; however, doses up to 20 mg/kg/day PO (Max: 1,000 mg/day) are used off-label. For extended-release oral suspension, 60 mg/kg single dose PO (Max: 2 g/dose). Safety and efficacy have not been established for IV; however, doses up to 10 mg/kg/day (Max: 500 mg/dose) have been used off-label.

1 year: For the immediate-release oral suspension or tablets, 10 mg/kg/day PO and single doses up to 30 mg/kg PO are the maximum FDA-approved dosages; however, doses up to 20 mg/kg/day PO are used off-label. For extended-release oral suspension, 60 mg/kg single dose PO. Safety and efficacy have not been established for IV; however, doses up to 10 mg/kg/day have been used off-label.
• Infants

  6 to 11 months: For the immediate-release oral suspension or tablets, 10 mg/kg/day PO and single doses up to 30 mg/kg PO are the maximum FDA-approved dosages; however, doses up to 20 mg/kg/day PO are used off-label. For extended-release oral suspension, 60 mg/kg single dose PO. Safety and efficacy have not been established for IV; however, doses up to 10 mg/kg/day have been used off-label.

  3 to 5 months: Safety and efficacy have not been established; however, doses up to 20 mg/kg/day PO or 10 mg/kg/day IV have been used off-label.

  1 to 2 months: Safety and efficacy have not been established; however, doses up to 20 mg/kg/day PO have been used off-label.

• Neonates

  Safety and efficacy have not been established; however, doses up to 20 mg/kg/day PO have been used off-label.

Patients with Hepatic Impairment Dosing

Dosage adjustment recommendations are not available; azithromycin has not been studied in patients with impaired hepatic function.[28855]

Patients with Renal Impairment Dosing

CrCl more than 80 mL/min: No dosage adjustment is needed.

CrCl 10 to 80 mL/min: No dosage adjustment is recommended.

CrCl less than 10 mL/min: No dosage adjustment is recommended; however, the manufacturer recommends caution in patients with severe renal impairment since mean AUC is increased roughly 35%.[28855][43974]

† Off-label indication

Revision Date: 04/13/2020 07:28:42 PM

References


59799 – Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines 2015. MMWR. 2015;64(3):1-137


65198 – Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect
2020 Mar. [Epub ahead of print]


**How Supplied**

<table>
<thead>
<tr>
<th><strong>Azithromycin Lyophilisate for solution for injection</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Azithromycin 2.5g Powder for Injection</strong> (00703-9089) (Teva Pharmaceuticals USA)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (60505-6076) (Apotex Corp)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (70860-0100) (Athenex Pharmaceutical Division LLC)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (55150-0174) (AuroMedics Pharma LLC)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (10019-0648) (Baxter Anesthesia/Critical Care) (off market)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (63323-0398) (Fresenius Kabi USA, LLC)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (10019-0648) (Hikma Pharmaceuticals USA inc.) (off market)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (00409-0144) (Hospira Worldwide, Inc., a Pfizer Company)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (25021-0112) (Sagent Pharmaceuticals) (off market)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (70436-0019) (Slate Run Pharmaceuticals, LLC)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (62756-0512) (Sun Pharmaceutical Industries, Inc.)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (00703-9085) (Teva Pharmaceuticals USA) (off market)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection</strong> (50111-0794) (Teva Pharmaceuticals USA)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection (NOVAPLUS)</strong> (70860-0125) (Athenex Pharmaceutical Division LLC)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection (NOVAPLUS)</strong> (63323-0398) (Fresenius Kabi USA, LLC)</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Powder for Injection (PREMIER ProRx)</strong> (63323-0398) (Fresenius Kabi USA, LLC)</td>
</tr>
<tr>
<td><strong>Zithromax 500mg Powder for Injection</strong> (00069-3150) (Pfizer Inc.) (off market)</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Azithromycin Lyophilisate for solution for injection</td>
</tr>
<tr>
<td>Azithromycin Ophthalmic drops, solution</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Azithromycin Oral capsule</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
</tr>
</tbody>
</table>

https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&type=0&printSections=monindi&printSections=monsup&printSections=mo... 28/139
### Azithromycin Oral tablet

<table>
<thead>
<tr>
<th>Azithromycin 250mg Tablet</th>
<th>60687-0282 (American Health Packaging) (off market)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>68084-0443 (American Health Packaging)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>68084-0656 (American Health Packaging) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>68084-0278 (American Health Packaging)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>68084-0906 (American Health Packaging) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>60687-0282 (American Health Packaging)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>68084-0278 (American Health Packaging)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>68084-0906 (American Health Packaging) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>60687-0282 (American Health Packaging)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>65862-0641 (Aurobindo Pharma USA Inc.)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>50268-0098 (AvPAK; a Division of AvKARE Inc) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>50268-0098 (AvPAK; a Division of AvKARE Inc) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>50268-0100 (AvPAK; a Division of AvKARE Inc) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>50268-0103 (AvPAK; a Division of AvKARE Inc) (off market)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>50268-0098 (AvPAK; a Division of AvKARE Inc)</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet</td>
<td>69452-0171 (Bionpharma Inc)</td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (59762-3060) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (59762-2198) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (68180-0160) (Lupin Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00904-6010) (Major Pharmaceuticals Inc, a Harvard Drug Group Company) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00904-6708) (Major Pharmaceuticals Inc, a Harvard Drug Group Company)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00904-6010) (Major Pharmaceuticals Inc, a Harvard Drug Group Company) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00904-6405) (Major Pharmaceuticals Inc, a Harvard Drug Group Company) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (63739-0575) (McKesson Packaging) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (51079-0591) (Mylan Institutional LLC)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (51079-0040) (Mylan Institutional LLC)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (43063-0090) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (43063-0524) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (43063-0090) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (55289-0964) (PD-Rx Pharmaceuticals, Inc.)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (43063-0572) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (43063-0728) (PD-Rx Pharmaceuticals, Inc.)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (33358-0040) (RxChange Co.)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00781-1496) (Sandoz Inc. a Novartis Company) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00781-5776) (Sandoz Inc. a Novartis Company)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00781-8089) (Sandoz Inc. a Novartis Company)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (51224-0022) (TAGI Pharma, Inc.)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (00093-7146) (Teva Pharmaceuticals USA) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (50111-0787) (Teva Pharmaceuticals USA) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (50111-0787) (Teva Pharmaceuticals USA) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (50111-0787) (Teva Pharmaceuticals USA)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (64679-0961) (Wockhardt USA, LLC) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet</strong> (64679-0961) (Wockhardt USA, LLC)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (60505-2581) (Apotex Corp)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (60505-2581) (Apotex Corp) (off market)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (65862-0641) (Aurobindo Pharma USA Inc.)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (70882-0107) (Cambridge Therapeutics Technologies, LLC)</td>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=mo...32/139" alt="Image" /></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (59762-3060) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (59762-2198) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (68180-0160) (Lupin Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (00378-1533) (Mylan Pharmaceuticals Inc.)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (00781-5776) (Sandoz Inc. a Novartis Company) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 250mg Tablet (6ct Blister Card)</strong> (00781-1496) (Sandoz Inc. a Novartis Company) (off market)</td>
<td></td>
</tr>
</tbody>
</table>
## Azithromycin Oral tablet

<table>
<thead>
<tr>
<th>Azithromycin 250mg Tablet (6ct Blister Card)</th>
<th>Sandoz Inc. a Novartis Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin 250mg Tablet (6ct Blister Card)</td>
<td>TAGI Pharma, Inc.</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet (6ct Blister Card)</td>
<td>Teva Pharmaceuticals USA</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet (6ct Blister Card)</td>
<td>Wockhardt USA, LLC</td>
</tr>
<tr>
<td>Azithromycin 250mg Tablet (6ct Blister Card)</td>
<td>off market</td>
</tr>
<tr>
<td>Zithromax 250mg Tablet</td>
<td>NuCare Pharmaceuticals Inc</td>
</tr>
<tr>
<td>Zithromax 250mg Tablet</td>
<td>PD-Rx Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Zithromax 250mg Tablet</td>
<td>PD-Rx Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Zithromax 250mg Tablet</td>
<td>PD-Rx Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Zithromax 250mg Tablet</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Zithromax 250mg Tablet</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Zithromax Z-PAK 250mg Tablet</strong> (00069-3060) (Pfizer Inc.)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (68084-0279) (American Health Packaging) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (68084-0913) (American Health Packaging) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (60687-0271) (American Health Packaging)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (68084-0279) (American Health Packaging)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (60505-2582) (Apotex Corp)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (65862-0642) (Aurobindo Pharma USA Inc.)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (50268-0099) (AvPAK; a Division of AvKARE Inc) (off market)</td>
<td></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (50268-0101) (AvPAK; a Division of AvKARE Inc) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (50268-0099) (AvPAK; a Division of AvKARE Inc)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (50268-0104) (AvPAK; a Division of AvKARE Inc) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (69452-0172) (Bionpharma Inc)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (70882-0108) (Cambridge Therapeutics Technologies, LLC) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (59762-3070) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (68180-0161) (Lupin Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (00904-6011) (Major Pharmaceuticals Inc, a Harvard Drug Group Company) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (55289-0274) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (43063-0540) (PD-Rx Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>---</td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (43063-0568) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td><img src="1.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (55289-0274) (PD-Rx Pharmaceuticals, Inc.) (off market)</td>
<td><img src="2.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (43063-0506) (PD-Rx Pharmaceuticals, Inc.)</td>
<td><img src="3.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (43063-0713) (PD-Rx Pharmaceuticals, Inc.)</td>
<td><img src="4.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (00781-1941) (Sandoz Inc. a Novartis Company) (off market)</td>
<td><img src="5.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (00781-5789) (Sandoz Inc. a Novartis Company)</td>
<td><img src="6.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (51224-0122) (TAGI Pharma, Inc.)</td>
<td><img src="7.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (00093-7169) (Teva Pharmaceuticals USA)</td>
<td><img src="8.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (50111-0788) (Teva Pharmaceuticals USA)</td>
<td><img src="9.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (50111-0788) (Teva Pharmaceuticals USA) (off market)</td>
<td><img src="10.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (64679-0964) (Wockhardt USA, LLC)</td>
<td><img src="11.png" alt="Image" /></td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet</strong> (64679-0964) (Wockhardt USA, LLC) (off market)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-W964.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (60505-2582) (Apotex Corp) (off market)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-APC-AZ500.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (60505-2582) (Apotex Corp)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-APC-AZ500.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (65862-0642) (Aurobindo Pharma USA Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-AZ500.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (70882-0118) (Cambridge Therapeutics Technologies, LLC)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-L3070.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (59762-3070) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-L12.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (68180-0161) (Lupin Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-LUPIN.png" alt="Image" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (00378-1534) (Mylan Pharmaceuticals Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="https://clinicalkeycontent.blob.core.windows.net/content/assets/images/monographs/pharmacology/53/139/Azithromycin-500mg-Tablet-UNIV.png" alt="Image" /></td>
<td></td>
</tr>
</tbody>
</table>
### Azithromycin Oral tablet

#### Azithromycin 500mg Tablet (3ct Blister Card) (55289-0274) (PD-Rx Pharmaceuticals, Inc.) (off market)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
</tbody>
</table>

#### Azithromycin 500mg Tablet (3ct Blister Card) (00781-1941) (Sandoz Inc. a Novartis Company) (off market)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
</tbody>
</table>

#### Azithromycin 500mg Tablet (3ct Blister Card) (00781-5789) (Sandoz Inc. a Novartis Company) (off market)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
</tbody>
</table>

#### Azithromycin 500mg Tablet (3ct Blister Card) (00781-8090) (Sandoz Inc. a Novartis Company)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
</tbody>
</table>

#### Azithromycin 500mg Tablet (3ct Blister Card) (51224-0122) (TAGI Pharma, Inc.)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
</tbody>
</table>

#### Azithromycin 500mg Tablet (3ct Blister Card) (00093-7169) (Teva Pharmaceuticals USA) (off market)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
</tbody>
</table>

#### Azithromycin 500mg Tablet (3ct Blister Card) (50111-0788) (Teva Pharmaceuticals USA)

<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&amp;type=0&amp;printSections=monindi&amp;printSections=monsup&amp;printSections=monsup" alt="Image" /></td>
<td>Azithromycin tablets 500 mg</td>
</tr>
<tr>
<td>Azithromycin Oral tablet</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (64679-0964) (Wockhardt USA, LLC) (off market)</td>
<td></td>
</tr>
<tr>
<td><img src="image1" alt="Azithromycin 500mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 500mg Tablet (3ct Blister Card)</strong> (64679-0964) (Wockhardt USA, LLC)</td>
<td></td>
</tr>
<tr>
<td><img src="image2" alt="Azithromycin 500mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Zithromax 500mg Tablet</strong> (00069-3070) (Pfizer Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="image3" alt="Zithromax 500mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Zithromax Tri-Pak 500mg Tablet</strong> (00069-3070) (Pfizer Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="image4" alt="Zithromax Tri-Pak 500mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (68084-0464) (American Health Packaging)</td>
<td></td>
</tr>
<tr>
<td><img src="image5" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (68084-0920) (American Health Packaging) (off market)</td>
<td></td>
</tr>
<tr>
<td><img src="image6" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (60687-0920) (American Health Packaging)</td>
<td></td>
</tr>
<tr>
<td><img src="image7" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (60505-2583) (Apotex Corp)</td>
<td></td>
</tr>
<tr>
<td><img src="image8" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (69452-0173) (Bionpharma Inc)</td>
<td></td>
</tr>
<tr>
<td><img src="image9" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (59762-3080) (Greenstone Ltd)</td>
<td></td>
</tr>
<tr>
<td><img src="image10" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (68180-0162) (Lupin Pharmaceuticals, Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="image11" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin 600mg Tablet</strong> (00378-1535) (Mylan Pharmaceuticals Inc.)</td>
<td></td>
</tr>
<tr>
<td><img src="image12" alt="Azithromycin 600mg Tablet" /></td>
<td></td>
</tr>
</tbody>
</table>
### Azithromycin Oral tablet

| **Azithromycin 600mg Tablet** (00781-5793) (Sandoz Inc. a Novartis Company) |
| ![Image](image1.png) |
| **Azithromycin 600mg Tablet** (00781-1497) (Sandoz Inc. a Novartis Company) (off market) |
| ![Image](image2.png) |
| **Azithromycin 600mg Tablet** (51224-0222) (TAGI Pharma, Inc.) |
| **Azithromycin 600mg Tablet** (00093-7147) (Teva Pharmaceuticals USA) (off market) |
| **Azithromycin 600mg Tablet** (50111-0789) (Teva Pharmaceuticals USA) |
| **Azithromycin 600mg Tablet** (50111-0789) (Teva Pharmaceuticals USA) (off market) |
| **Azithromycin 600mg Tablet** (64679-0962) (Wockhardt USA, LLC) (off market) |
| ![Image](image3.png) |
| **Azithromycin 600mg Tablet** (64679-0962) (Wockhardt USA, LLC) |
| ![Image](image4.png) |
| **Zithromax 600mg Tablet** (00069-3080) (Pfizer Inc.) |
| ![Image](image5.png) |

### Azithromycin Powder for oral suspension

| **Azithromycin 1g Single-Dose Powder for Suspension** (59762-3051) (Greenstone Ltd) |
| ![Image](image6.png) |
| **Zithromax 1g Single-Dose Powder for Suspension** (00069-3051) (Pfizer Inc.) |
| ![Image](image7.png) |

https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&type=0&printSections=monindi&printSections=monsup&printSections=mono... 41/139
<table>
<thead>
<tr>
<th>Product Name</th>
<th>NDC/Reference</th>
<th>Company/Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin Powder for oral suspension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azithromycin 100mg/5ml Powder for Suspension</td>
<td>(59762-3110)</td>
<td>Greenstone Ltd</td>
</tr>
<tr>
<td>Azithromycin 100mg/5ml Powder for Suspension</td>
<td>(00185-7203)</td>
<td>Sandoz Inc. a Novartis Company</td>
</tr>
<tr>
<td>Azithromycin 100mg/5ml Powder for Suspension</td>
<td>(00093-7148)</td>
<td>Teva Pharmaceuticals USA (off market)</td>
</tr>
<tr>
<td>Azithromycin 100mg/5ml Powder for Suspension</td>
<td>(00093-2027)</td>
<td>Teva Pharmaceuticals USA</td>
</tr>
<tr>
<td>Azithromycin 100mg/5ml Powder for Suspension</td>
<td>(00093-7148)</td>
<td>Teva Pharmaceuticals USA (off market)</td>
</tr>
<tr>
<td>Azithromycin 100mg/5mL Powder for Suspension</td>
<td>(50111-0793)</td>
<td>Teva Pharmaceuticals USA (off market)</td>
</tr>
<tr>
<td>Azithromycin 100mg/5mL Powder for Suspension</td>
<td>(59651-0007)</td>
<td>Aurobindo Pharma Limited</td>
</tr>
<tr>
<td>Azithromycin 100mg/5mL Powder for Suspension</td>
<td>(42806-0147)</td>
<td>Epic Pharma LLC</td>
</tr>
<tr>
<td>Azithromycin 100mg/5mL Powder for Suspension</td>
<td>(43386-0470)</td>
<td>Gavis Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>Azithromycin 100mg/5mL Powder for Suspension</td>
<td>(70710-1457)</td>
<td>Zydus Pharmaceuticals (USA) Inc.</td>
</tr>
<tr>
<td>Azithromycin 100mg/5mL Powder for Suspension</td>
<td>(00069-3110)</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>(59762-3140)</td>
<td>Greenstone Ltd</td>
</tr>
</tbody>
</table>
Azithromycin Powder for oral suspension

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Ref. Number</th>
<th>Company/Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>59762-3130</td>
<td>Greenstone Ltd</td>
</tr>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>59762-3120</td>
<td>Greenstone Ltd</td>
</tr>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>00185-7209</td>
<td>Sandoz Inc., a Novartis Company</td>
</tr>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>00185-7212</td>
<td>Sandoz Inc., a Novartis Company</td>
</tr>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>00185-7206</td>
<td>Sandoz Inc., a Novartis Company</td>
</tr>
<tr>
<td>Azithromycin 200mg/5ml Powder for Suspension</td>
<td>00093-7149</td>
<td>Teva Pharmaceuticals USA (off market)</td>
</tr>
</tbody>
</table>

Azithromycin 200mg/5ml Powder for Suspension (00093-2026) (Teva Pharmaceuticals USA)

Azithromycin 200mg/5ml Powder for Suspension (00093-7149) (Teva Pharmaceuticals USA) (off market)

Azithromycin 200mg/5ml Powder for Suspension (50111-0767) (Teva Pharmaceuticals USA) (off market)

Azithromycin 200mg/5ml Powder for Suspension (50111-0791) (Teva Pharmaceuticals USA) (off market)
Azithromycin Powder for oral suspension

Azithromycin 200mg/5mL Powder for Suspension (50111-0792) (Teva Pharmaceuticals USA) (off market)

Azithromycin 200mg/5mL Powder for Suspension (59651-0008) (Aurobindo Pharma Limited)

Azithromycin 200mg/5mL Powder for Suspension (42806-0149) (Epic Pharma LLC)

Azithromycin 200mg/5mL Powder for Suspension (42806-0151) (Epic Pharma LLC)

Azithromycin 200mg/5mL Powder for Suspension (42806-0150) (Epic Pharma LLC)

Azithromycin 200mg/5mL Powder for Suspension (43386-0471) (Gavis Pharmaceuticals, LLC, wholly owned subsidiary of Lupin)

Azithromycin 200mg/5mL Powder for Suspension (70710-1459) (Zydus Pharmaceuticals (USA) Inc.)

Azithromycin 200mg/5mL Powder for Suspension (70710-1460) (Zydus Pharmaceuticals (USA) Inc.)

Azithromycin 200mg/5mL Powder for Suspension (70710-1458) (Zydus Pharmaceuticals (USA) Inc.)

Zithromax 200mg/5mL Powder for Suspension (00069-3130) (Pfizer Inc.)

Zithromax 200mg/5mL Powder for Suspension (00069-3120) (Pfizer Inc.)

Zithromax 200mg/5mL Powder for Suspension (00069-3140) (Pfizer Inc.)
Azithromycin Powder for oral suspension, extended release

<table>
<thead>
<tr>
<th>Zmax 2g Extended-Release Powder for Suspension (00069-4170) (Pfizer Inc.)</th>
</tr>
</thead>
</table>

Zmax 2g Extended-Release Powder for Suspension (00069-4170) (Pfizer Inc.) (off market)

Zmax Pediatric 2g Extended-Release Powder for Suspension (00069-4170) (Pfizer Inc.) (off market)

Description/Classification

Description

Azithromycin is a semisynthetic antibiotic belonging to the macrolide subgroup of azalides and is similar in structure to erythromycin. Azithromycin offers the advantage that it can be dosed once daily and produces less GI intolerance than does erythromycin. Azithromycin has a wider spectrum of activity than erythromycin against Mycobacterium avium complex (MAC), Haemophilus influenzae, nontuberculous mycobacteria, and Chlamydia trachomatis. Another apparent advantage over erythromycin is that azithromycin reaches higher intracellular concentrations, thus increasing its efficacy and duration of action.[50470] These advantages are demonstrated in studies that show that single doses of azithromycin are effective for the treatment of acute otitis media and sexually transmitted diseases (STDs) due to chlamydia and gonorrhea.[23529][24204][51748] Azithromycin is better tolerated and offers shorter treatment durations compared with clarithromycin.[50470] Azithromycin is used for the treatment of a variety of respiratory infections, including otitis media, pharyngitis/tonsillitis, pertussis, community-acquired pneumonia, and sinusitis.[28855][51747] However, macrolides are not recommended for empiric monotherapy of acute bacterial sinusitis due to high rates of Streptococcus pneumoniae resistance (approximately 30%).[49853] Azithromycin is also used for the treatment of STDs due to chlamydia and gonorrhea, and for the prophylaxis and treatment of Mycobacterium avium complex (MAC) disease.[34361][43632] An ophthalmic preparation is used for the treatment of bacterial conjunctivitis.[43976]

Long-term azithromycin is used off-label to improve lung function and decrease pulmonary exacerbation in cystic fibrosis patients 6 years and older who have sputum cultures persistently positive for P. aeruginosa.[51770] Additionally, long-term azithromycin may be used as an add-on therapy in adults with moderate to severe asthma. Prior to starting therapy, sputum should be checked for atypical mycobacteria.[64807] While azithromycin has been studied in regimens for H. pylori eradication and some studies show efficacy, the azithromycin-containing regimens have not been as effective as regimens containing clarithromycin in terms of eradication rates.[51749][51750] Macrolide cross-resistance is also an issue.[51751]

Updates for coronavirus disease 2019 (COVID-19):

Available data regarding the use of azithromycin as adjunctive treatment of COVID-19 due to SARS-CoV-2 are limited and inconclusive. Azithromycin is being used in some COVID-19 protocols based on preliminary data; however, the risk of adverse events, particularly when given in combination with chloroquine or hydroxychloroquine (e.g., cardiac arrhythmias), should be considered. In an open-label, non-randomized clinical trial of hydroxychloroquine (n = 26), azithromycin was administered in combination with hydroxychloroquine to prevent bacterial superinfection in 6 patients. On day 6, all patients treated with the combination (hydroxychloroquine and azithromycin) were virologically cured compared to 57.1% of patients treated with hydroxychloroquine alone (n= 20). [65147] Another small study (n = 11) reviewed the same azithromycin plus hydroxychloroquine regimen and found nasopharyngeal swabs were still positive for SARS-CoV-2 in 8 of 10 patients 5 to 6 days after treatment initiation. [65198] In a retrospective analysis of a multicenter cohort study (n = 349) in patients with Middle East Respiratory
Coronavirus (MERS-CoV), 136 patients received macrolide therapy in combination with antiviral treatment. Macrolide therapy was not associated with a reduction in 90-day mortality compared to the control group. [65149]

Classifications

- General Anti-infectives Systemic
  - Systemic Antibiotics
    - Macrolide Antibiotics

- Sensory Organs
  - Ophthalmologicals
    - Ophthalmological Anti-infectives

References


43632 – Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines 2010. MMWR. 2010;59:1-110


https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&type=0&printSections=monindi&printSections=monsup&printSections=mo
Administration Information

General Administration Information

For storage information, see the specific product information within the How Supplied section.

Route-Specific Administration

Oral Administration

Oral Solid Formulations

- May be taken with or without food; however, increased tolerability has been observed when the tablets are taken with food.[28855][43975]

Oral Liquid Formulations

Oral suspension (immediate-release, bottles for reconstitution):

- Review the reconstitution instructions for the particular product and package size, as the amount of water required for reconstitution may vary from manufacturer to manufacturer.
- Tap the bottle to loosen the powder. Add water in 2 portions and shake well after each portion.
- Azithromycin for oral suspension (100 mg/5 mL or 200 mg/5 mL strengths) may be taken with or without food.
- Measure dosage with a calibrated spoon, cup, or oral syringe.
- Storage after reconstitution: Store at 5 to 30 degrees C (41 to 86 degrees F). Discard any unused portion per manufacturer recommendations.[28855]

Oral suspension (1 gram single-dose packet):

https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&type=0&printSections=monindi&printSections=monsup&printSections=mosup
• Do not use for administration of doses other than 1 gram.
• Zithromax for oral suspension (1-g single-dose packet) may be taken with or without food; however, administration with food may increase tolerability.
• Mix the entire contents of the packet in 60 mL (approximately 2 ounces) of water. Administer the entire contents immediately, then add an additional 60 mL of water, mix and administer to assure complete administration of the dosage.[43975]

**Oral suspension (extended-release, bottles for reconstitution):**

• Extended-release oral suspension (2 grams azithromycin) should be taken as a single dose at least 1 hour before or 2 hours after a meal.
• If a patient vomits within 5 minutes of the dose, the manufacturer recommends additional antibiotic treatment due to minimal absorption of the azithromycin dose. If a patient vomits between 5 to 60 minutes following the dose, consider alternate therapy. In patients with normal gastric emptying, if vomiting occurs 60 minutes or later after the dose, no additional antibiotic therapy is warranted. In patients with delayed gastric emptying, consider alternative therapy.
• Constitute with 60 mL of water, replace cap, and shake bottle well.
• *Storage after reconstitution:* Do not refrigerate. Use within 12 hours.[34473]

**Injectable Administration**

• Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit.

**Intravenous Administration**

*Reconstitution:*

**NOTE:** *When using the Vial-Mate drug reconstitution device, please refer to the Vial-Mate instructions for assembly and reconstitution.*[43974]

• Add 4.8 mL of Sterile Water Injection to a concentration of 100 mg/mL.
• Because the vial is supplied under vacuum, it is recommended that a standard 5 mL (non-automated) syringe be used to ensure that the exact amount of 4.8 mL of sterile water is dispensed.
• Shake until all of the drug is dissolved.
• Further dilution is required.
• *Storage:* The reconstituted solution is stable for 24 hours when stored below 30 degrees C (86 degrees F).[43974]

**Dilution:**

• Dilute by transferring 5 mL of the reconstituted solution into a compatible diluent; use 500 mL of diluent for a concentration of 1 mg/mL and 250 mL of diluent for a concentration of 2 mg/mL.
• Compatible diluents include: 0.9% Sodium Chloride Injection, 0.45% Sodium Chloride Injection, 5% Dextrose Injection, Lactated Ringer's Injection, 5% Dextrose and 0.45% Sodium Chloride Injection with 20 mEq KCl, 5% Dextrose and Lactated Ringer's Injection, 5% Dextrose and 0.3% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, Normosol-M and 5% Dextrose Injection, and Normosol-R and 5% Dextrose Injection.
• *Storage:* Diluted solutions are stable for 24 hours at or below room temperature (30 degrees C or 86 degrees F) or for 7 days if stored under refrigeration (5 degrees C or 41 degrees F).[43974]
**Intravenous infusion:**

- Do not administer intramuscularly or via IV bolus.
- Other intravenous substances, additives, or medications should not be added to azithromycin or infused simultaneously through the same IV line.
- For a dose of 500 mg in 250 mL (concentration = 2 mg/mL), infuse over 1 hour. For a dose of 500 mg in 500 mL (concentration = 1 mg/mL), infuse over 3 hours.[43974]

**Ophthalmic Administration**

- For ophthalmic use only. Apply topically only to the eye.
- Instruct patient on proper instillation of eye solution.
- Avoid contamination of the eye solution; do not touch the tip of the eye dropper to the eye, fingertips, or other surface.
- Due to the difficulty of administering eye drops to pediatric patients, consider a 2 person administration approach to ensure proper installation of the drops (1 person to hold the eyelids open and 1 person to administer the drops).
- To avoid contamination, do not share an opened bottle among patients.[43976]

---

**Clinical Pharmaceutics Information**

From Trissel's 2™ Clinical Pharmaceutics Database

**Azithromycin**

1. **pH Range**

   pH 6.4 to 6.6

**References**


2. **Stability**

   Azithromycin injection in intact containers stored as directed by the manufacturer is stable until the labeled expiration date. The manufacturer indicates the reconstituted azithromycin injection is stable for 24 hours at controlled room temperature. Infusion Solutions: The manufacturer indicates that azithromycin diluted to 1 to 2 mg/mL is stable for 24 hours at room temperature and 7 days refrigerated in the infusion solutions noted below. Dextrose 5% Dextrose 5% in lactated Ringer's Dextrose 5% in sodium chloride 0.3% Dextrose 5% in sodium chloride 0.45% Dextrose 5% in sodium chloride 0.45% with potassium chloride 20 mEq/L Lactated Ringer's injection Normosol-M in dextrose 5% Normosol-R in dextrose 5% Sodium chloride 0.45% Sodium chloride 0.9%

**References**

Anon. Manufacturer's information and labeling. (Package insert).
3. pH Effects

Zhang et al. evaluated the stability of azithromycin in aqueous solution over a pH range of 4 to 7.2. They reported that azithromycin in aqueous solution exhibits maximum stability at pH 6.3. Below pH 6.0, the decomposition rate is rapid. At pH above 6.3 the rate of degradation increases with increasing pH. Mareno et al. similarly reported nearly total loss of azithromycin in hydrochloric acid and sodium hydroxide solutions with a concentration of 0.1 mol/L. Fiese et al. evaluated the stability of azithromycin in aqueous solution over the acidic pH range 1.0 to 4.1. Azithromycin underwent extensive decomposition at acidic pH. The time for 10% decomposition to occur at pH 2 was determined to be about 20 minutes at 37 degree C. The authors also reported that a ten-fold improvement in azithromycin stability occurred for each unit of pH increase within the tested range.

References


4. Light Exposure

Azithromycin in solution has been shown to undergo increased decomposition if exposed to sunlight and ultraviolet light.

References


5. Other Information

Trace metals- Zhang et al. reported that the presence of EDTA does not alter the rate of azithromycin decomposition in solution indicating that trace metal ions are not likely to be involved in the degradation of azithromycin.

References


6. Stability Max

Maximum reported stability periods: Reconstituted solution- 24 hours at room temperature. In infusion solutions- 24 hours at room temperature and 7 days refrigerated

References

Anon. Manufacturer's information and labeling. (Package insert).
Compounding Drug Information
From Trissel's 2™ Clinical Pharmaceutics Database

Azithromycin

1. Identity/Properties

Azithromycin occurs as a white or almost white crystalline material. Solubility: Azithromycin is practically insoluble in water but freely soluble in dehydrated ethanol and dichloromethane. pH: Azithromycin oral suspension has a pH between 8.5 and 11. Reconstituted azithromycin injection at 100 mg/mL is buffered with citric acid to a pH of 6.4 to 6.6. pKa: Azithromycin has apparent pKa values of 9.16 and 9.37.

References


Anon. Manufacturer's information and labeling. (Package insert and bulk material data sheet).


2. General Stability Info

Azithromycin bulk powder and oral suspension powder should be packaged in tight containers and stored at controlled room temperature. Azithromycin oral capsules and tablets should be packaged in well-closed containers and stored at controlled room temperature. Single-dose packets of oral suspension powder should be stored between 5 and 30degree C. Azithromycin for injection vials should be stored at controlled room temperature. Reconstituted azithromycin oral suspension should be stored between 5 and 30degree C. After reconstitution, the oral suspension should be used according to the manufacturer's labeling for the specific product. Reconstituted azithromycin injection at 100 mg/mL is stable for 24 hours at controlled room temperature. Diluted for use to 1 to 2 mg/mL in a compatible infusion solution, the drug is stable for 24 hours at controlled room temperature and for seven days refrigerated.

References


Anon. Manufacturer's information and labeling. (Package insert and bulk material data sheet).

3. Enteral Feeds
Klang et al. evaluated the compatibility of azithromycin oral suspension 200 mg/5 mL with Osmolite 1.2 (Abbott). Five milliliters of the drug was vortex mixed with 5 mL of the enteral nutrition product for one minute. The sample was placed in an incubated shaker at 37 degree C for one hour. The mixture was evaluated for its ability to pass through a glass funnel stem (simulating a feeding tube). The portion of the mixture that passed through the funnel stem was filtered through a 100-micron filter and evaluated for retained solid matter. The test mixture passed through the glass funnel stem and did not demonstrate solid clumps upon filtration. Azithromycin oral suspension was reported to be compatible with Osmolite 1.2.

References


4. Rectal

Kauss et al. (2012) screened several compounded dosage forms of azithromycin for potential rectal administration in children who cannot take oral dosage forms. A rectal suspension, two rectal gels, a hard gelatin capsule, and a polyethylene glycol (PEG) suppository formulation were assessed; the suppository was selected as the best candidate dosage form for further development. Kauss et al. (2013) then developed and evaluated the stability of a pediatric PEG azithromycin rectal suppository formulation. Each suppository contained azithromycin 419 mg (equivalent to anhydrous azithromycin 400 mg), PEG 1500 1760 mg, and PEG 4000 440 mg. The suppositories were prepared in three ways: as suspended, co-melted, and solid solution suppositories. The solid solution suppositories proved to be the preferred form. They were prepared by melting the PEGs at 90 degree C using a water bath and then adding the azithromycin powder. The mixture was stirred until a homogenous limpid mixture was obtained. The mixture was cooled to 55 to 60 degree C and was poured into 2-g suppository moulds. The suppositories were allowed to harden at room temperature in a dessicator for 24 hours. The stability of the solid solution azithromycin suppositories was evaluated at 40 degree C and 75% relative humidity for 12 weeks packaged in alu/alu foil blisters (SGM India) and plastic moulds. In plastic moulds the suppositories underwent unacceptable changes including drug loss. However, in the alu/alu blisters the suppositories were much more stable. No change in the appearance and melting point of the suppositories occurred. HPLC analysis, differential scanning calorimetry, FTIR analysis, and X-ray diffraction found the azithromycin to be stable throughout the 12-week study period. In vitro drug release was unchanged, and in vivo bioavailability in rabbits was comparable to oral azithromycin.

References


5. Ophthalmic

Ophthalmic preparations, like other sterile drugs, should be prepared in a suitable clean air environment using appropriate aseptic procedures. When prepared from non-sterile components, an appropriate and effective sterilization method must be employed. Mareno et al. evaluated factors that affect the stability of azithromycin ophthalmic solution. The ophthalmic solution had an azithromycin concentration of 1.667 mg/mL in an unspecified physiological solution. The ophthalmic solution was subjected to a variety of stresses to observe the effects on the drug’s stability. A microbiological assay technique was used to assess stability. Extremes of pH were evaluated using hydrochloric acid and sodium hydroxide 0.1 mol/L along with heat of 70 degree C; these resulted in nearly total loss of the drug in six hours. Exposure to hydrogen peroxide 0.3% yielded a similar result. Exposure of the azithromycin ophthalmic solution to sunlight and...
ultraviolet light (at 254 and 284 nm) resulted in losses of 11, 38, and 20%, respectively, in 48 hours. The authors concluded that azithromycin ophthalmic solution pH and exposure to light should be controlled for stability.

References


Adverse Reactions

- abdominal pain
- acute generalized exanthematous pustulosis (AGEP)
- agitation
- anaphylactic shock
- anaphylactoid reactions
- anemia
- angioedema
- anorexia
- anosmia
- anxiety
- arthralgia
- asthenia
- atopic dermatitis
- azotemia
- blurred vision
- bronchospasm
- candidiasis
- chest pain (unspecified)
- chills
- cholestasis
- conjunctivitis
- constipation
- contact dermatitis
- corneal erosion
- cough
- diaphoresis
- diarrhea
- dizziness
- drowsiness
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- dysgeusia
- dysosmia
- dyspepsia
- dyspnea
- dysuria
- eczema vaccinatum
- edema
- elevated hepatic enzymes
- emotional lability
- eosinophilia
- erythema
- erythema multiforme
- fatigue
- fever
- flatulence
- gastritis
The most common adverse reactions in patients receiving systemic regimens of azithromycin were gastrointestinal-related, which tended to be more frequent in the single-dose oral regimens in adults and higher doses in pediatrics. Among the most commonly reported gastrointestinal adverse events were diarrhea or loose stools (4% to 14% of adults; 1.8% to 10% of pediatric patients), nausea (1.8% to 18% adults; 0.4% to 4% pediatrics), vomiting (up to 13% adults; 1.1% to 14% pediatrics), abdominal pain (1.9% to 14% adults; 1.2% to 4% pediatrics), flatulence (up to 5% adults; up to 1% pediatric patients), and anorexia (2% adults; up to 1% pediatrics). Adverse GI effects occurring in up to 1% of adult and pediatric patients included gastritis, constipation, and dyspepsia. In adults, melena, oral moniliasis, and mucositis were also reported in up to 1%; stomatitis was reported by 1.9% of adults. In pediatric patients, enteritis was reported in up to 1%. In HIV-infected patients receiving prophylactic azithromycin (i.e., 1,200 mg once weekly) for disseminated Mycobacterium avium complex (MAC) the incidences of the following GI-related adverse events were higher than other patient populations: diarrhea or loose stools (12.9% to 52.8%), nausea (27% to 32.6%), abdominal pain (27% to 32.2%), dyspepsia (4.7% to 9%), flatulence (9% to 10.7%), vomiting (6.7% to 9%), and anorexia 2.1%. Postmarketing adverse gastrointestinal reactions have also included pancreatitis and rare reports of tongue discoloration. [28855] [34473] [43974] [43975]

In clinical trials, elevated hepatic enzymes (ALT, AST) occurred in 4% to 6% of patients receiving intravenous azithromycin. Elevations of ALT (SGPT), GGT, and AST (SGOT) occurred with an incidence of 1% to 2% in patients receiving oral therapy. Hyperbilirubinemia was noted in up to 3% of patients. Up to 1% of drug recipients experienced cholestasis with jaundice. Postmarketing reports indicate that systemic azithromycin has been associated with
abnormal liver function including cholestatic jaundice, hepatitis as well as rare cases of hepatic necrosis and hepatic failure, some of which have resulted in death.[28855] [34473] [43974] [43975]

Microbial overgrowth and superinfection can occur with antibiotic use. C. difficile-associated diarrhea (CDAD) or pseudomembranous colitis has been reported with azithromycin. If pseudomembranous colitis is suspected or confirmed, ongoing antibacterial therapy not directed against C. difficile may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, C. difficile-directed antibacterial therapy, and surgical evaluation as clinically appropriate. Other infections reported during treatment with systemic azithromycin therapy during clinical trials included vaginitis (up to 2.8%), fungal superinfection (less than 1%), and fungal dermatitis (less than 1%). Cases of oral candidiasis (thrush) and vaginitis have also been noted during postmarketing use of the drug.[28855] [34473] [43974] [43975] [43976]

Hematologic adverse reactions noted in more than 1% of patients treated with systemic azithromycin during clinical trials included decreased hemoglobin, hematocrit, lymphocytes (lymphopenia), and neutrophils; as well as increased platelet counts, lymphocytes (lymphocytosis), neutrophils, and eosinophils (eosinophilia). Leukopenia, neutropenia, decreased platelet counts, elevated monocytes, and elevated basophils have been reported in less than 1% of adults. In children, anemia and leukopenia occurred in up to 1% of patients. Thrombocytopenia and mild neutropenia have been reported during postmarketing surveillance.[28855] [34473] [43974] [43975]

Respiratory adverse reactions have been reported in up to 1% of pediatric patients receiving azithromycin. These adverse reactions have included asthma, bronchitis, cough, pharyngitis, pleural effusion, and rhinitis. Dyspnea has been noted in 1.9% of patients receiving the intravenous formulation of azithromycin and in up to 1% of pediatric patients.[28855] [34473] [43974] [43975] Nasal congestion and sinusitis have been reported in less than 1% of patients receiving the ophthalmic preparation of azithromycin.[43976]

An injection site reaction has been associated with the administration of intravenous azithromycin. Approximately 12% of patients treated for pneumonia experienced a side effect related to the intravenous infusion; most common were pain at the injection site (6.5%) and local inflammation or erythema (3.1%). Application site reactions occurred in 1.9% of patients receiving infusions for pelvic inflammatory disease.[43974]

During clinical trials, recipients of systemic azithromycin reported fatigue (up to 3.9%), fever (2.1%), malaise (up to 1.1%), pain (up to 1%), chills and influenza-like symptoms (less than 1%), paresthesias (less than 1%), and asthenia (less than 1%). Cases of asthenia, paresthesias, fatigue, and malaise have also been noted during postmarketing use of the drug.[28855] [34473] [43974] [43975]

Central nervous system (CNS) adverse reactions have been associated with the use of systemic azithromycin. In patients receiving systemic formulations of azithromycin during clinical trials, vertigo (up to 1%), headache (up to 5%), dizziness (up to 3.9%), and somnolence or drowsiness (up to 1%) were reported. Additional CNS adverse reactions noted in less than 1% of pediatric drug recipients included agitation, nervousness, emotional lability, hostility, hyperkinesia, insomnia, and irritability. Postmarketing CNS effects have also included convulsions (seizures), hyperactivity, and syncope. Postmarketing psychiatric adverse reactions include aggression and anxiety.[28855] [34473] [43974] [43975]

Cardiovascular adverse reactions associated with systemic azithromycin therapy reported in up to 1% of patients include chest pain (unspecified) and palpitations. Although uncommon, these are potentially serious adverse reactions. In postmarketing experience, there have been reports of arrhythmias including ventricular tachycardia, hypotension, QT prolongation, and torsade de pointes.[28855] [34473] [43974] [43975]

Conjunctivitis and uveitis were reported in up to 1% of patients receiving systemic azithromycin. Taste perversion (dysgeusia) was reported in up to 1.3% of patients receiving systemic azithromycin and in less than 1% of patients using the ophthalmic preparation. Decreased hearing (0.9% to 1.1%) and tinnitus (0.9% and 3.4%) were noted by patients receiving weekly azithromycin doses of 1,200 mg. During postmarketing use of systemic azithromycin, cases of dysgeusia, dysosmia (smell perversion) and anosmia (loss of smell), and hearing disturbances including hearing loss, deafness or tinnitus have been reported.[28855] [34473] [43974] [43975] [43976]

Dermatological and hypersensitivity-related adverse reactions have been reported with azithromycin therapy. During clinical trials, a generalized rash was reported in up to 8.1% of azithromycin recipients. More specifically, rashes were noted in 1% of adult patients receiving oral therapy, up to 5% of pediatric patients, 1.9% of patients receiving IV
therapy, 3.4% to 8.1% of patients receiving a 1,200 mg once weekly dose, and in less than 1% of patients receiving ophthalmic therapy. Maculopapular rash and vesicular rash were reported in up to 1% of drug recipients. Patients also reported episodes of pruritus (up to 3.9%) and arthralgia (up to 3%). Other, less frequently reported adverse reactions (up to 1%) included photosensitivity, urticaria, bronchospasm, angioedema, and diaphoresis. Adverse events reported in less than 1% of patients using the ophthalmic solution included contact dermatitis, hives, and periocular swelling. Eczema vaccinatum (atopic dermatitis) was reported in up to 1% of pediatric patients, while dermatitis was noted in 2% of pediatric patients. Cases of angioedema, arthralgia, edema, photosensitivity, pruritus, rash, and urticaria have also been noted during postmarketing use. Serious skin reactions including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Azithromycin therapy should be withdrawn if there are signs and symptoms of an allergic reaction. Some patients have a recurrence of allergic symptoms once symptomatic treatment is withdrawn, even though azithromycin therapy is not reinstituted. Correlation between the long tissue half-life and duration of allergic symptoms has not yet been determined. Anaphylaxis (anaphylactoid reactions, anaphylactic shock) has been reported, including fatal cases.[28855][34473][43974][43975][43976]

Systemic azithromycin therapy has been associated with cases of acute generalized exanthematous pustulosis (AGEP). The nonfollicular, pustular, erythematous rash starts suddenly and is associated with a fever above 38 degrees C. Typically, the first episode of AGEP appears 2 to 3 weeks after exposure to the inciting drug; however, unintentional reexposure may cause a second episode within 2 days.[27736][43974]

Ocular irritation was the most frequently reported adverse reaction after ophthalmic administration of azithromycin and occurred in approximately 1% to 2% of patients. Other reported adverse reactions occurring in less than 1% of patients included blurred vision, corneal erosion, ocular erosion, ocular pain (burning, stinging, and irritation upon instillation), ocular pruritus, punctate keratitis, visual impairment (reduced visual acuity), and xerophthalmia.[43976]

The exacerbation of myasthenia gravis symptoms as well as the new onset of myasthenic syndrome have been reported with systemic azithromycin therapy. While rare, this side effect has been reported with other macrolide antibacterial agents.[28855][34473][43974][43975]

Laboratory abnormalities have been noted with systemic azithromycin use. These include decreased bicarbonate (up to 1%), increased bicarbonate (less than 1%), hyperkalemia (1% to 2%), hypokalemia (less than 1%), hyponatremia (less than 1%), hyperglycemia and hypoglycemia (up to 1%), elevated phosphokinase (1% to 2%), elevated serum alkaline phosphatase (less than 1%), elevated LDH (up to 3%), and elevated phosphate (less than 1%).[28855][34473][43974][43975]

An increased relapse rate of cancers of the blood or lymph nodes (i.e., leukemia, lymphoma), including death, has been observed in allogeneic stem cell transplant patients who were receiving azithromycin as prophylaxis for bronchiolitis obliterans syndrome (BOS). In a clinical trial (n = 480) evaluating the effectiveness of long-term azithromycin to prevent BOS in patients who undergo donor stem cell transplants for cancers of the blood or lymph nodes, cancer relapse was observed in 32.9% of azithromycin-treated patients vs. 20.8% of patients who were given a placebo. The 2-year survival rate was 56.6% in azithromycin-treated patients vs. 70.1% in those given a placebo. [63410]

Renal adverse reactions in patients receiving systemic regimens of azithromycin included nephritis (up to 1% adults) and dysuria (up to 1% pediatric patients). Elevated BUN (azotemia) and elevated creatinine occurred in up to 1% of patients, with elevated creatinine reported in 4% to 6% of patients receiving IV therapy. Postmarketing adverse reactions have also included acute renal failure (unspecified) and interstitial nephritis.[28855][34473][43974][43975]

Azithromycin has been associated with infantile hypertrophic pyloric stenosis (IHPS), particularly in newborns younger than 2 weeks of age. In a retrospective study of 148 infants given azithromycin during the first 14 days of life, IHPS developed in 3 patients (2%) for an odds ratio (OR) of 8.26 (95% CI: 2.62 to 26; p < 0.001). Of 729 infants aged 15 to 42 days at the time of azithromycin exposure, 5 patients developed IHPS for an OR of 2.98 (95% CI: 1.24 to 7.2; p = 0.015). No infants aged 43 to 90 days at the time of azithromycin exposure developed IHPS. A male predominance was also observed, as all 8 infants who developed IHPS were boys. IHPS was also reported in 2 former 32-week premature infants (2 out of 3 triplets) who received 5 days of azithromycin after hospitalization at 7 weeks of age. The infants were diagnosed with IHPS at 89 and 94 days of age, respectively, and both infants underwent surgical pyloromyotomies. Infants, particularly males who receive azithromycin within the first few weeks
of life, should be closely monitored for signs and symptoms of IHPS for 6 weeks after azithromycin treatment. Pyloric stenosis rarely affects infants older than 3 months.[57925] [57926] Pyloric stenosis has been noted in postmarketing reports.[28855]

References


Contraindications/Precautions

Absolute contraindications are italicized.

- hepatitis
- jaundice
- macrolide hypersensitivity
- allogeneic stem cell transplant
- apheresis
- AV block
- bradycardia
- breast-feeding
- cardiomyopathy
- celiac disease
- contact lenses
- diarrhea
- females
- fever
- geriatric
- heart failure
- hepatic disease
- human immunodeficiency virus (HIV) infection
- hyperparathyroidism
- hypocalcemia
- hypokalemia
- hypomagnesemia
- hypothermia
- hypothyroidism
- infants
- leukemia
Azithromycin does not treat viral infection (e.g., common cold). Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Patients should be told to complete the full course of treatment, even if they feel better earlier.

Azithromycin is contraindicated in patients with a known azithromycin or macrolide hypersensitivity. Azithromycin has a rare risk of serious hypersensitivity reactions or anaphylaxis, including angioedema and severe dermatologic reactions, including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, and toxic epidermal necrolysis. Fatalities associated with these severe reactions have been reported. There is a risk of cross sensitivity with other macrolide antibiotics. Some patients have a recurrence of allergic symptoms once symptomatic treatment is withdrawn, even though azithromycin therapy is not reinstated.[28855] [43974]

Systemic azithromycin is contraindicated in patients with a history of jaundice and/or hepatic dysfunction associated with the prior use of azithromycin. Systemically administered azithromycin should be used with caution in patients who have hepatic disease. In addition, abnormal hepatic function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported with use, including cases that have resulted in death. Monitor liver function tests in patients receiving systemic azithromycin. Discontinue treatment immediately if signs and symptoms of hepatitis and liver dysfunction occur.[28855]

Safe use of systemically-administered azithromycin in patients with severe renal impairment has not been determined; limited data are available. Azithromycin should be used cautiously in patients with preexisting severe renal impairment or renal failure (CrCl less than 10 ml/min).[28855]

Almost all antibacterial agents, including systemic azithromycin, have been associated with pseudomembranous colitis or C. difficile-associated diarrhea (CDAD) which may range in severity from mild to life-threatening. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Consider pseudomembranous colitis in patients presenting with diarrhea after antibacterial use. Careful medical history is necessary as pseudomembranous colitis has been reported to occur over 2 months after the administration of antibacterial agents. If pseudomembranous colitis is suspected or confirmed, ongoing antibacterial therapy not directed against C. difficile may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, C. difficile-directed antibacterial therapy, and surgical evaluation as clinically appropriate. [28855]

Macrolides are associated with QT prolongation; cases of cardiac arrhythmias and torsade de pointes (TdP) have been reported during postmarketing surveillance.[34473] Caution is warranted when using the drug in high-risk patients, including those with known prolongation of the QT interval or a history of TdP.[34473] Use azithromycin with caution in patients with conditions that may increase the risk of QT prolongation including congenital long QT syndrome, bradycardia, AV block, heart failure, stress-related cardiomyopathy, myocardial infarction, stroke, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte imbalances. Females, geriatric patients, patients with sleep deprivation, pheochromocytoma, sickle cell disease, hypothyroidism, hyperparathyroidism, hypothermia, systemic inflammation (e.g., human immunodeficiency virus (HIV) infection, fever, and some autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus (SLE), and celiac disease) and patients undergoing apheresis procedures (e.g., plasmapheresis [plasma
In patients taking azithromycin with another drug that prolongs the QT interval (see Therapeutic Drug Monitoring for recommendations specific to using azithromycin with chloroquine or hydroxychloroquine in the treatment of COVID-19), obtain a pre-treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG device. Obtain baseline electrolytes, including calcium, magnesium, and potassium. Determine if the patient is currently on any QT-prolonging medications that can be discontinued. Document high-risk cardiovascular and comorbid conditions. If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging medications, and proceed with close QTc surveillance. Obtain an initial on-therapy QTc approximately 2 to 4 hours after the first dose and then again at 48 and 96 hours after treatment initiation. If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal males), or 480 to 499 msec (postpubertal females), correct contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging medications, and obtain an initial on-therapy QTc 48 and 96 hours after treatment initiation. If the baseline QTc is less than 460 msec (prepubertal), less than 470 msec (postpubertal males), or less than 480 msec (postpuberual females), correct electrolyte abnormalities and obtain an initial on-therapy QTc 48 and 96 hours after treatment initiation.[65170] Data from a cohort study in adults have associated azithromycin with an increased risk of cardiovascular death. The study included persons receiving prescriptions for azithromycin (n = 347,795), amoxicillin (n = 1,348,672), ciprofloxacin (n = 264,626), levofloxacin (n = 193,906), and matched persons receiving no antibiotics (n = 1,391,180). Analysis of the data found those persons receiving a 5-day course of azithromycin had a significantly greater risk of cardiovascular death than persons not treated with antibiotics (HR: 2.88; 95% CI: 1.79 to 4.63; p less than 0.001), persons treated with 5 days of amoxicillin (HR: 2.49; 95% CI: 1.38 to 4.50; p = 0.002), and persons in the first 5 days of ciprofloxacin therapy (HR: 3.49; 95% CI: 1.32 to 9.26; p = 0.01); mortality rate did not differ from levofloxacin.[50182] [50183]

Clinical trials of oral and intravenous azithromycin and other reported clinical experience has not identified overall differences in safety and effectiveness between geriatric and younger adult subjects. Greater sensitivity of some older individuals cannot be ruled out. Health care providers are advised that geriatric patients may be more susceptible to drug-associated effects on the QT interval.[28855] [43974] The federal Omnibus Budget Reconciliation Act (OBRA) regulates medication use in residents of long-term care facilities. According to OBRA, use of antibiotics should be limited to confirmed or suspected bacterial infections. Antibiotics are non-selective and may result in the eradication of beneficial microorganisms while promoting the emergence of undesired ones, causing secondary infections such as oral thrush, colitis, or vaginitis. Any antibiotic may cause diarrhea, nausea, vomiting, anorexia, and hypersensitivity reactions.[60742]

Available data over several decades with systemic azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Developmental toxicity studies in animals showed no drug-induced fetal malformations at doses up to 4 times the adult human daily dose of 500 mg based on body surface area; however, decreased viability and delayed development were observed in the offspring of pregnant rats given azithromycin at a dose equivalent to 4 times the adult human daily dose from day 6 of pregnancy through weaning.[28855] In a nested, case-control study (n = 87,020 controls; 8,702 cases) within the Quebec Pregnancy Cohort, systemic azithromycin use during early pregnancy was associated with an increased risk of spontaneous abortion (adjusted odds ratio (aOR) 1.65, 95% CI 1.34 to 2.02, 110 exposed cases); residual confounding by severity of infection may be a potential limitation of this study.[62176] In a large population-based cohort study (n = 104,605 live births) assessing systemic macrolide (n = 8,632) or penicillin (n = 95,973) use during pregnancy and the risk of major malformations, macrolide use in the first trimester was associated with increased risk of any malformation (27.7 vs. 17.7 per 1,000 live births; adjusted risk ratio 1.55, 95% CI 1.19 to 2.03), and in particular, cardiovascular malformations (10.6 vs. 6.6 per 1,000 live births; adjusted risk ratio 1.62, 95% CI 1.05 to 2.51). Specific findings for azithromycin use during the first trimester were precluded due to few events. Macrolide use during the second and third trimesters showed no increased risk of any major malformation (19.5 vs. 17.3 per 1,000 live births; adjusted risk ratio 1.13, 95% CI 0.94 to 1.36); however, a borderline association with gastrointestinal malformations was observed (adjusted risk ratio 1.89, 95% CI 1.19 to 3.58). Macrolide use in any trimester was associated with an increased risk of genital malformations (adjusted odds ratio (aOR) 1.46, 95% CI 1.04 to 2.06, 35 exposed cases).[62177]
Azithromycin is present in human breast milk. Non-serious adverse reactions have been reported in breast-fed infants after maternal administration of azithromycin. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for azithromycin and any potential adverse effects on the breast-fed infant from azithromycin or the underlying maternal condition. Monitor the breast-fed infant for diarrhea, vomiting, or rash. There are no available data on the effects of azithromycin on milk production. Azithromycin breast milk concentrations were measured in 20 women receiving a single 2 g oral dose during labor. Azithromycin was present in breast milk up to 4 weeks after dosing. Another study of 8 women receiving azithromycin IV before incision of cesarean section showed azithromycin was present in breast milk up to 48 hours later. A prospective observational study assessing the safety of macrolide antibiotics during lactation found that 12.7% (n = 55) of babies exposed to macrolides via breast milk experienced adverse events including rash, diarrhea, loss of appetite, and somnolence. The adverse event rate was similar to that seen in babies in a control group whose mothers were treated with amoxicillin (8.3%). Only 10 mothers in the study received azithromycin, 6 received clarithromycin, 2 received erythromycin, and the remainder were treated with roxithromycin. A population-based cohort study found that babies diagnosed with infantile hypertrophic pyloric stenosis were 2.3 to 3 times more likely to have been exposed to a macrolide antibiotic through breast milk during the first 90 days of life than babies not exposed during that same time period. The study did not specify which antibiotic the mothers of affected babies were prescribed; however, the majority of macrolide prescriptions were for erythromycin (72%), with 7% for azithromycin and 1.7% for clarithromycin. Previous American Academy of Pediatrics (AAP) recommendations consider erythromycin to be usually compatible with breast-feeding; azithromycin has not been evaluated by the AAP.

Use azithromycin with caution and with proper monitoring in young infants and neonates; there have been reports of infantile hypertropic pyloric stenosis (IHPS) occurring in young infants after azithromycin therapy. Because azithromycin is sometimes used for the treatment of conditions that are associated with significant mortality or morbidity (e.g., pertussis), weigh the benefit of azithromycin therapy against the potential risk of developing IHPS. Inform parents and other caregivers to contact their physician if vomiting or irritability with feeding occurs. In a retrospective study of 148 infants given azithromycin during the first 14 days of life, IHPS developed in 3 patients (2%) for an odds ratio of 8.26 (95% CI: 2.62 to 26; p less than 0.001). Of 729 infants aged 15 to 42 days at the time of azithromycin exposure, 5 patients developed IHPS for an OR of 2.98 (95% CI: 1.24 to 7.2; p = 0.015). A male predominance was also observed, as all 8 infants who developed IHPS were boys. No infants aged 43 to 90 days at the time of azithromycin exposure developed IHPS; however, there have been 2 case reports of older infants developing IHPS (89 and 94 days old at diagnosis, respectively).

Direct sunlight (UV) exposure should be minimized during therapy with systemic azithromycin. Photosensitivity has been reported as an adverse reaction to azithromycin. Some intravenous formulations of azithromycin contain a total of 4.96 mEq (114 mg) of sodium per 500-mg vial. The sodium amounts should be considered in patients with requirements for sodium restriction or blunted natriuresis to salt loading (i.e., cardiac disease or hypertension).

Patients who wear contact lenses should avoid wearing them while being treated for an ocular infection with azithromycin ophthalmic solution.

Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving systemic azithromycin therapy.

While azithromycin may be used to treat certain sexually transmitted diseases (STD), the drug may mask or delay the symptoms of incubating syphilis when given as part of an STD treatment regimen. All patients with a diagnosed or suspected STD should be tested for other STDs, which may include HIV, syphilis, chlamydia, and gonorrhea, at the time of diagnosis. Initiate appropriate therapy and perform follow-up testing as recommended based upon sexually transmitted disease diagnosis.

Do not use azithromycin for long-term prophylaxis of bronchiolitis obliterans syndrome (BOS) in patients with cancers of the blood or lymph nodes (i.e. leukemia, lymphoma) who undergo an allogeneic stem cell transplant because of the increased risk for cancer relapse or death.

Revision Date: 04/10/2020 04:39:06 PM
References


59799 – Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines 2015. MMWR. 2015;64(3):1-137


Mechanism of Action

Azithromycin inhibits protein synthesis in bacterial cells by binding to the 50S subunit of bacterial ribosomes. Action is generally bacteriostatic but can be bactericidal in high concentrations or against susceptible organisms. Azithromycin is more active against gram-negative organisms but has less activity against streptococci and staphylococci than does erythromycin; erythromycin-resistant gram-positive isolates demonstrate cross-resistance to azithromycin.[34473] [50470] Azithromycin concentrates in phagocytes and fibroblasts leading to high intracellular concentrations. Drug distribution to inflamed tissues is thought to occur from the concentration in phagocytes.[43975]

The susceptibility interpretive criteria for azithromycin are delineated by pathogen. The MICs are defined for beta-hemolytic streptococci, S. viridans group, and S. pneumoniae as susceptible at 0.5 mcg/mL or less, intermediate at 1 mcg/mL, and resistant at 2 mcg/mL or more. The MICs are defined for Staphylococcus sp. as susceptible at 2 mcg/mL or less, intermediate at 4 mcg/mL, and resistant at 8 mcg/mL or more. The MICs are defined for S. enterica ser. Typhi as susceptible at 16 mcg/mL or less and resistant at 32 mcg/mL or more. The MICs are defined for H. influenzae and H. parainfluenzae as susceptible at 4 mcg/mL or less. The MICs are defined for N. meningitidis as susceptible at 2 mcg/mL or less, which may be only appropriate for prophylaxis of meningococcal case contacts and does not apply to treatment of invasive disease. The MICs are defined for N. gonorrhoeae as susceptible at 1 mcg/mL or less, presuming use of a 1 g single dose regimen that includes an additional antimicrobial agent.[63320] [63321]

Macrolides have been reported to have immunomodulatory properties in pulmonary inflammatory disorders. They may downregulate inflammatory responses and reduce the excessive cytokine production associated with respiratory viral infections; however, their direct effects on viral clearance are uncertain. Immunomodulatory mechanisms may include reducing chemotaxis of neutrophils (PMNs) to the lungs by inhibiting cytokines (i.e., IL-8), inhibition of mucus hypersecretion, decreased bacterial adhesion to the epithelium, decreased production of reactive oxygen species, accelerating neutrophil apoptosis, and blocking the activation of nuclear transcription factors.[65149] [65150] [65151] [65152] [65153]

References

Azithromycin is administered orally, intravenously, and topically to the eye. Following systemic administration, it is widely distributed to body tissues and fluids including bone, prostate, ovary, uterus, stomach, liver, middle ear, lung, tonsils and adenoids, and sputum. Azithromycin exhibits significant intracellular penetration and concentrates within fibroblasts and phagocytes. As a result, tissue concentrations are significantly higher than are plasma concentrations. Azithromycin is distributed widely into brain tissue but not into cerebrospinal fluid or the aqueous humor of the eye. Protein binding varies with plasma concentration; 51% of the drug is bound at low concentrations (0.02 mcg/ml) and this binding decreases to 7% at higher concentrations (2 mcg/ml). Azithromycin has a long half-life in both adults (40 to 68 hours) and children (32 to 64 hours), which is partially explained by its extensive tissue uptake and slow release. Elimination is largely in the feces, following excretion into the bile, with less than 14% excreted in the urine.

**Affected cytochrome P450 isoenzymes and drug transporters:** none

**Route-Specific Pharmacokinetics**

- **Oral Route**

  *Immediate-release suspension*
Peak concentrations of azithromycin occur approximately 2 hours after administration. Food increases the Cmax by approximately 56%, but the extent of absorption is unaltered.

Single-dose (1 g) immediate-release suspension

Administration with food increased the Cmax by 46% and the AUC by 14%.

250 mg and 500 mg immediate-release tablets

The absolute bioavailability is approximately 38%. The Cmax for a 5-day regimen of 250 mg PO ranged from 0.24 to 0.43 mcg/mL and the AUC was 14.9 mcg x hour/mL. The Cmax for 3-day regimen of 500 mg PO ranged from 0.44 to 0.54 mcg/mL and the AUC was 17.4 mcg x hour/mL. Food increases the Cmax by approximately 23%, but the extent of absorption is unaltered.

600 mg immediate-release tablets

The absolute bioavailability is 34%. For a 1,200 mg dose, the Cmax is 0.33 mcg/mL, the Tmax is 2.5 hours, and the AUC is 6.8 mcg x hour/mL. Administration with food increased the Cmax by 31%; however, the AUC was unchanged.

Extended-release suspension

The bioavailability of the extended-release suspension compared to the immediate-release suspension is 83%. Food increases absorption. Administration with a high-fat meal increased the Cmax by 115% and the AUC by 23% compared to the fasted state. Administration with a standard meal increased the Cmax by 119% and the AUC by 12%.

Extended-release suspension and immediate-release formulations are not bioequivalent and cannot be interchanged.

Intravenous Route

Azithromycin doses of 500 mg IV daily administered over 1 hour for 2 to 5 days resulted in a mean Cmax +/- SD of 3.63 +/- 1.60 mcg/mL, a 24-hour trough of 0.20 +/- 0.15 mcg/mL, and an AUC\textsubscript{24} of 9.60 +/- 4.80 mcg x hour/mL. Doses of 500 mg IV administered over 3 hours resulted in a mean Cmax of 1.14 +/- 0.14 mcg/mL, a 24-hour trough of 0.18 +/- 0.02 mcg/mL, and an AUC\textsubscript{24} of 8.03 +/- 0.86 mcg x hour/mL. Similar pharmacokinetic values were obtained in patients that received the same 3-hour IV infusion regimen for 2 to 5 days. A comparison of the pharmacokinetics after the first and fifth daily doses showed an increase in AUC\textsubscript{24} of 61%, reflecting a 3-fold rise in trough concentrations. Cmax increased by 8%.

Other Route(s)

Ophthalmic Route

The systemic concentration of azithromycin after ocular administration is estimated to be below quantifiable limits (10 ng/mL or less).
Special Populations

- **Hepatic Impairment**

  Azithromycin pharmacokinetics have not been studied in patients with hepatic impairment. Azithromycin is not substantially metabolized.[28855]

- **Renal Impairment**

  After the oral administration of a single 1,000 mg oral dose of azithromycin, mean Cmax was increased by 5.1% and the AUC increased by 4.2% in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/minute) compared to subjects with normal renal function (GFR greater than 80 mL/minute). The Cmax and AUC of azithromycin are increased by 61% and 35%, respectively, in patients with severe renal impairment (GFR less than 10 mL/minute).[28855]

- **Pediatrics**

  *Immediate-release oral formulations:*

  *Children and Adolescents 6 to 15 years*

  In a pharmacokinetic study in pediatric patients 6 years to 15 years who received 10 mg/kg azithromycin orally on day 1, followed by 5 mg/kg orally on days 2 to 5, mean Cmax, AUC, and clearance were 0.383 mcg/mL, 3.109 mcg x hour/mL, and 4.27 L/kg/hour, respectively.[51756] [51760]

  *Infants and Children 6 months to 5 years*

  Maximum plasma concentrations (Cmax) and area under the curve (AUC) have been reported to be lower, and clearance has been reported to be higher for younger pediatric patients compared with older patients. In a pharmacokinetic study in pediatric patients 6 months to 5 years who received azithromycin 10 mg/kg orally on day 1, followed by 5 mg/kg orally on days 2 to 5, mean Cmax, AUC, and clearance were 0.224 mcg/mL, 1.841 mcg x hour/mL, and 2.27 L/kg/hour, respectively. Mean elimination half-life was 32 hours. [51755] [51756]

  *Extended-release suspension:*

  *Infants, Children, and Adolescents 3 months to 16 years*

  The pharmacokinetics of azithromycin were characterized after a single 60 mg/kg dose in pediatric patients 3 months to 16 years. Although there was high inter-patient variability in systemic exposure (AUC and Cmax) across the age groups studied, individual azithromycin AUC and Cmax values in pediatric patients were comparable to or higher than those after administration of 2 g extended-release suspension in adults. [34473]

  *Intravenous formulation:*

  *Infants, Children, and Adolescents 6 months to 15 years*

  In a pharmacokinetic study in pediatric patients (6 months to less than 16 years), after a single azithromycin IV dose of 10 mg/kg (Max: 500 mg/dose), mean peak concentration was 2.4 mcg/mL,
clearance was 15.3 mL/minute/kg, and elimination half-life was 65 hours. Peak concentrations occurred 1 hour after administration. No differences in pharmacokinetic parameters were noted among different age groups.[31756]

- **Geriatric**
  The pharmacokinetic parameters of azithromycin in older volunteers (65 to 85 years) were similar to those in younger volunteers for a 5-day oral regimen.[28855]

- **Gender Differences**
  No significant differences in azithromycin pharmacokinetics occur based on gender.[28855]

References


Pregnancy

Available data over several decades with systemic azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Developmental toxicity studies in animals showed no drug-induced fetal malformations at doses up to 4 times the adult human daily dose of 500 mg based on body surface area; however, decreased viability and delayed development were observed in the offspring of pregnant rats given azithromycin at a dose equivalent to 4 times the adult human daily dose from day 6 of pregnancy through weaning.[28855] In a nested, case-control study (n = 87,020 controls; 8,702 cases) within the Quebec Pregnancy Cohort, systemic azithromycin use during early pregnancy was associated with an increased risk of spontaneous abortion (adjusted odds ratio (aOR) 1.65, 95% CI 1.34 to 2.02, 110 exposed cases); residual confounding by severity of infection may be a potential limitation of this study.[62176] In a large population-based cohort study (n = 104,605 live births) assessing systemic macrolide (n = 8,632) or penicillin (n = 95,973) use during pregnancy and the risk of major malformations, macrolide use in the first trimester was associated with increased risk of any malformation (27.7 vs. 17.7 per 1,000 live births; adjusted risk ratio 1.55, 95% CI 1.19 to 2.03), and in particular, cardiovascular malformations (10.6 vs. 6.6 per 1,000 live births; adjusted risk ratio 1.62, 95% CI 1.05 to 2.51).

Specific findings for azithromycin use during the first trimester were precluded due to few events. Macrolide use during the second and third trimesters showed no increased risk of any major malformation (19.5 vs. 17.3 per 1,000 live births; adjusted risk ratio 1.13, 95% CI 0.94 to 1.36); however, a borderline association with gastrointestinal malformations was observed (adjusted risk ratio 1.89, 95% CI 1 to 3.58). Macrolide use in any trimester was associated with an increased risk of genital malformations (adjusted risk ratio 1.58, 95% CI 1.14 to 2.19), mainly hypospadias.[65012] Additionally, in another large population-based cohort study (n = 139,938 live births) assessing systemic antibiotic exposure during the first trimester of pregnancy (n = 15,469 exposures) and the risk of major birth defects, macrolide exposure was associated with an increased risk of digestive system malformations (adjusted odds ratio (aOR) 1.46, 95% CI 1.04 to 2.06, 35 exposed cases).[62177]

Breast-Feeding

Azithromycin is present in human breast milk. Non-serious adverse reactions have been reported in breast-fed infants after maternal administration of azithromycin. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for azithromycin and any potential adverse effects on the breast-fed infant from azithromycin or the underlying maternal condition. Monitor the breast-fed infant for diarrhea, vomiting, or rash. There are no available data on the effects of azithromycin on milk production. Azithromycin breast milk concentrations were measured in 20 women receiving a single 2 g oral dose during labor. Azithromycin was present in breast milk up to 4 weeks after dosing. Another study of 8 women receiving azithromycin IV before incision of cesarean section showed azithromycin was present in breast milk up to 48 hours later.[28855] A prospective observational study assessing the safety of macrolide antibiotics during lactation found that 12.7% (n = 55) of babies exposed to macrolides via breast milk experienced adverse events including rash, diarrhea, loss of appetite, and somnolence. The adverse event rate was similar to that seen in babies in a control group whose mothers were treated with amoxicillin (8.3%). Only 10 mothers in the study received azithromycin, 6 received clarithromycin, 2 received erythromycin, and the remainder were treated with roxithromycin.[45767] A population-based cohort study found that babies diagnosed with infantile hypertrophic pyloric stenosis were 2.3 to 3 times more likely to have been exposed to a macrolide antibiotic through breast milk during the first 90 days of life than babies not exposed during that same time period. The study did not specify which antibiotic the mothers of affected babies were prescribed; however, the majority of macrolide prescriptions were for erythromycin (72%), with 7% for azithromycin and 1.7% for clarithromycin.[45779] Previous American Academy of Pediatrics (AAP) recommendations consider erythromycin to be usually compatible with breast-feeding; azithromycin has not been evaluated by the AAP.[27500]


Interactions

Level 1 (Severe)

- Cisapride
- Dronedarone
- Pimozide
- Thioridazine

Level 2 (Major)

- Aclidinium; Formoterol
- Albuterol
- Albuterol; Ipratropium
- Alfuzosin
- Amiodarone
- Amitriptyline
- Amitriptyline; Chlordiazepoxide
- Anagrelide
- Apomorphine
- Arformoterol
- Aripiprazole
- Arsenic Trioxide
- Artemether; Lumefantrine
- Asenapine
- Atomoxetine
- Bedaquiline
- Bismuth Subcitrate Potassium; Metronidazole; Tetracycline
- Bismuth Subsalicylate; Metronidazole; Tetracycline
- Budesonide; Formoterol
- Buprenorphine
- Buprenorphine; Naloxone
- Ceritinib
- Chloroquine
- Chlorpromazine
- Ciprofloxacin
- Citalopram
- Clofazimine
- Clomipramine
- Clozapine
- Codeine; Phenylephrine; Promethazine
- Codeine; Promethazine
- Crizotinib
- Dasatinib
- Degarelix
- Desflurane
- Desipramine
- Deutetrabenazine
- Dextromethorphan; Promethazine
- Dextromethorphan; Quinidine
- Disopyramide
- Dofetilide
- Dolasetro
- Dolutegravir; Rilpivirine
- Donepezil
- Donepezil; Memantine
- Doxepin
- Droperidol
- Efavirenz
- Efavirenz; Emtricitabine; Tenofovir Fumarate
- Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate
- Eliglustat
- Emtricitabine; Rilpivirine; Tenofovir alafenamide
- Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate
- Encorafenib
- Enflurane
- Entrectinib
- Eribulin
- Escitalopram
- Ezogabine
- Fingolimod
- Flecainide
- Fluconazole
- Fluoxetine
- Fluoxetine; Olanzapine
- Fluphenazine
- Fluticasone; Salmeterol
- Fluticasone; Umeclidinium; Vilanterol
- Fluticasone; Vilanterol
- Fluvoxamine
- Formoterol
- Formoterol; Mometasone
- Foscarnet
- Gemifloxacin
- Gemtuzumab Ozogamicin
- Gilteritinib
- Glasdegib
- Glycopyrrolate; Formoterol
- Goselrelin
- Granisetron
- Halogenated Anesthetics
- Haloperidol
- Halothane
- Histrelin
- Hydroxychloroquine
- Hydroxyzine
- Ibutilide
- Iloperidone
- Imipramine
- Indacaterol
- Indacaterol; Glycopyrrolate
- Inotuzumab Ozogamicin
- Isoflurane
- Itraconazole
- Ivosidenib
- Ketoconazole
- Lapatinib
- Lefamulin
- Lenvatinib
- Leuprolide
- Leuprolide; Norethindrone
- Levalbuterol
- Levofloxacin
- Lithium
- Lofexidine
- Long-acting beta-agonists
- Loperamide
- Loperamide; Simethicone
- Lopinavir; Ritonavir
- Macimorelin
- Maprotiline
- Mefloquine
- Meperidine; Promethazine
- Metaproterenol
- Methadone
- Metronidazole
- Midostaurin
- Mifepristone
- Mirtazapine
- Moxifloxacin
- Nilotinib
- Nortriptyline
- Octreotide
- Ofloxacin
- Olanzapine
- Olodaterol
- Ondansetron
- Osimertinib
- Oxaliplatin
- Paliperidone
- Panobinostat
- Pazopanib
- Pentamidine
- Perphenazine
- Perphenazine; Amitriptyline
- Phenylephrine; Promethazine
- Pimavanserin
- Pirbuterol
- Pitolisant
- Posaconazole
- Primaquine
- Procainamide
- Procyclidine
- Promethazine
- Propafenone
- Protriptyline
- Quetiapine
- Quinidine
- Quinine
- Ranolazine
- Ribociclib
- Ribociclib; Letrozole
- Rilpivirine
- Risperidone
- Romidepsin
- Salmeterol
- Saquinavir
- Sertraline
- Sevoflurane
- Short-acting beta-agonists
- Siponimod
- Sodium picosulfate; Magnesium oxide; Anhydrous citric acid
- Solifenacin
- Sorafenib
- Sotalol
- Sunitinib
- Tacrolimus
- Tamoxifen
- Telavancin
- Telithromycin
- Terbutaline
- Tiotropium; Olodaterol
- Tolterodine
- Toremifene
- Trazodone
- Tricyclic antidepressants
- Trifluoperazine
- Trimipramine
- Triptorelin
- Umeclidinium; Vilanterol
- Vandetanib
- Vardenafil
- Vemurafenib
- Venlafaxine
- Voriconazole
- Vorinostat
- Ziprasidone

**Level 3 (Moderate)**

- Aluminum Hydroxide
- Aluminum Hydroxide; Magnesium Carbonate
- Aluminum Hydroxide; Magnesium Hydroxide
- Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
- Aluminum Hydroxide; Magnesium Trisilicate
- Aspirin, ASA; Pravastatin
- Calcium Carbonate; Magnesium Hydroxide
- Colchicine
- Colchicine; Probenecid
- Conjugated Estrogens; Bazedoxifene
- Cyclosporine
- Dienogest; Estradiol valerate
- Digoxin
- Drospirenone
- Drospirenone; Estradiol
- Drospirenone; Ethinyl Estradiol
- Drospirenone; Ethinyl Estradiol; Levomefolate
- Estradiol; Levonorgestrel
- Estradiol; Norethindrone
- Estradiol; Norgestimate
- Ethinyl Estradiol
- Ethinyl Estradiol; Desogestrel
- Ethinyl Estradiol; Ethynodiol Diacetate
- Ethinyl Estradiol; Etonogestrel
- Ethinyl Estradiol; Levonorgestrel
- Ethinyl Estradiol; Levonorgestrel; Ferrous bisglycinate
- Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate
- Ethinyl Estradiol; Norelgestromin
- Ethinyl Estradiol; Norethindrone
- Ethinyl Estradiol; Norethindrone Acetate
- Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate
- Ethinyl Estradiol; Norethindrone; Ferrous fumarate
- Ethinyl Estradiol; Norgestimate
- Ethinyl Estradiol; Norgestrel
- Levonorgestrel
- Magnesium Hydroxide
- Mestranol; Norethindrone
- Nelfinavir
- Norethindrone
- Norgestrel
- Oral Contraceptives
- Pravastatin
- Segesterone Acetate; Ethinyl Estradiol
- Talazoparib
- Warfarin

**Level 4 (Minor)**

- Belladonna Alkaloids; Ergotamine; Phenobarbital
- Caffeine; Ergotamine
- Dihydroergotamine
- Ergotamine
- Fosphenytoin
- Phenytoin

**Aclidinium; Formoterol:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Albuterol:** (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]

**Albuterol; Ipratropium:** (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]

**Alfuzosin:** (Major) Avoid coadministration of azithromycin with alfuzosin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Alfuzosin may prolong the QT interval in a dose-dependent manner. [28261] [28855] [43974] [65157] [65170]

**Aluminum Hydroxide:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]

**Aluminum Hydroxide; Magnesium Carbonate:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]

**Aluminum Hydroxide; Magnesium Hydroxide:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]

**Aluminum Hydroxide; Magnesium Hydroxide; Simethicone:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]

**Aluminum Hydroxide; Magnesium Trisilicate:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]
Amiodarone: (Major) Avoid coadministration of amiodarone and azithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Amiodarone, a Class III antiarrhythmic agent, is associated with a well-established risk of QT prolongation and torsade de points (TdP). Although the frequency of TdP is less with amiodarone than with other Class III agents, amiodarone is still associated with a risk of TdP. Due to the extremely long half-life of amiodarone, a drug interaction is possible for days to weeks after discontinuation of amiodarone. Reports of QT prolongation and torsade de points (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation was reported in a 68-year-old woman receiving azithromycin and amiodarone. The patient had a history of stable congestive heart failure and a posterior communicating artery aneurysm. She was receiving amiodarone (200 mg/day) for over a year for paroxysmal atrial fibrillation. Additional medications included furosemide, enalapril, and aspirin. A regular sinus rhythm with normal P-R, QRST, and QTc intervals was noted prior to initiation of azithromycin therapy. Therapy with azithromycin was started at 500 mg PO on day 1, followed by 250 mg PO once daily for 4 days. Sinus bradycardia with marked QT prolongation and increased QT dispersion were noted on day 3 of treatment. Azithromycin was discontinued; QT and QTc intervals and QT dispersion returned to baseline in 4 days. Hypokalemia or hypomagnesemia were not noted in the patient and the amiodarone dose remained consistent at 200 mg/day. [28224] [28432] [28457] [28855] [43974] [65157] [65170]

Amitriptyline: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de points (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolog the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

Amitriptyline: Chlordiazepoxide: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de points (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolog the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

Anagrelide: (Major) Avoid coadministration of azithromycin with anagrelide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de points (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TdP and ventricular tachycardia have been reported with anagrelide. In addition, dose-related increases in mean QTc and heart rate were observed in healthy subjects. [28855] [30163] [43974] [65157] [65170]

Apopomorphine: (Major) Avoid coadministration of azithromycin with apomorphine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de points (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Limited data indicate that QT prolongation is also possible with apomorphine administration; the change in QTc interval is not significant in most patients receiving dosages within the manufacturer's guidelines. [28661] [28855] [43974] [65157] [65170]

Arformoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de points (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval...
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Aripiprazole:** (Major) Avoid coadministration of azithromycin with aripiprazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation has occurred during therapeutic use of aripiprazole and following overdose. [28855] [42845] [43974] [65157] [65170]

**Arsenic Trioxide:** (Major) Avoid coadministration of azithromycin with arsenic trioxide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TdP, QT interval prolongation, and complete atrioventricular block have been reported with arsenic trioxide use. [28226] [28855] [43974] [65157] [65170]

**Artemether; Lumefantrine:** (Major) Avoid coadministration of azithromycin with artemether; lumefantrine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Artemether; lumefantrine is associated with prolongation of the QT interval. [28432] [28855] [35401] [43974] [65157] [65170]

**Asenapine:** (Major) Avoid coadministration of azithromycin with asenapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Asenapine has been associated with QT prolongation. [28432] [28855] [36343] [43974] [65157] [65170]

**Aspirin, ASA; Pravastatin:** (Moderate) Azithromycin has the potential to increase pravastatin exposure when used concomitantly. Coadminister pravastatin and azithromycin cautiously due to a potential increased risk of myopathies. [45507]

**Atomoxetine: (Major) Avoid coadministration of azithromycin with atomoxetine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation has occurred during therapeutic use of atomoxetine and following overdose. [28405] [28855] [43974] [59321] [65157] [65170]

**Bedaquiline:** (Major) Avoid coadministration of azithromycin with bedaquiline due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Discontinue bedaquiline if evidence of serious ventricular arrhythmia or QTcF interval greater than 500 ms. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Bedaquiline prolongs the QT interval. [28855] [34329] [43974] [52746] [65157] [65170]

**Belladonna Alkaloids; Ergotamine; Phenobarbital:** (Minor) Carefully monitor patients when azithromycin and ergotamine are used concomitantly. Pharmacokinetic and/or pharmacodynamic interactions with ergotamine have been observed with other macrolides. [28858] [34473]

**Bismuth Subcitrate Potassium; Metronidazole; Tetracycline:** (Major) Avoid coadministration of azithromycin with metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been
spontaneously reported during azithromycin postmarketing surveillance. Potential QT prolongation has been reported in limited case reports with metronidazole. [28855] [43974] [57377] [57378] [65157] [65170]

**Bismuth Subsalicylate; Metronidazole; Tetracycline:** (Major) Avoid coadministration of azithromycin with metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Potential QT prolongation has been reported in limited case reports with metronidazole. [28855] [43974] [57377] [57378] [65157] [65170]

**Budesonide; Formoterol:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Buprenorphine:** (Major) Avoid coadministration of azithromycin with buprenorphine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. [28855] [41235] [43974] [60270] [65157] [65170]

**Buprenorphine; Naloxone:** (Major) Avoid coadministration of azithromycin with buprenorphine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. [28855] [41235] [43974] [60270] [65157] [65170]

**Caffeine; Ergotamine:** (Minor) Carefully monitor patients when azithromycin and ergotamine are used concomitantly. Pharmacokinetic and/or pharmacodynamic interactions with ergotamine have been observed with other macrolides. [28858] [34473]

**Calcium Carbonate; Magnesium Hydroxide:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]

**Ceritinib:** (Major) Avoid coadministration of azithromycin with ceritinib if possible due to the risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of ceritinib therapy, dose reduction, or discontinuation of therapy may be necessary if QT prolongation occurs. Ceritinib causes concentration-dependent QT prolongation. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28225] [43974] [57094] [65157] [65170]

**Chloroquine:** (Major) Avoid coadministration of chloroquine with azithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances (See Therapeutic Drug Monitoring for recommendations specific to COVID-19). Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is
increased with higher chloroquine doses. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28229] [28230] [28231] [28855] [29758] [43974] [65157] [65170]

Chlorpromazine: (Major) Avoid coadministration of azithromycin with chlorpromazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Chlorpromazine is associated with an established risk of QT prolongation and TdP. [28415] [28416] [28417] [28855] [43065] [43974] [65157] [65170]

Ciprofloxacin: (Major) Avoid coadministration of azithromycin with ciprofloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Rare cases of QT prolongation and TdP have been reported with ciprofloxacin during postmarketing surveillance. [28432] [28457] [28855] [29833] [33144] [33145] [33146] [43411] [43974] [48869] [48871] [65157] [65170]

Cisapride: (Severe) There have been case reports of QT prolongation and torsade de pointes (TdP) with the use of azithromycin in post-marketing reports. Azithromycin is contraindicated with other drugs that have been specifically established that have a causal association with QT prolongation and torsade de pointes, such as cisapride. [28407] [28855] [43974]

Citalopram: (Major) Avoid coadministration of azithromycin with citalopram due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Citalopram causes dose-dependent QT interval prolongation. [28269] [28855] [43974] [65157] [65170]

Clofazimine: (Major) Avoid coadministration of azithromycin with clofazimine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation and TdP have been reported in patients receiving clofazimine in combination with QT prolonging medications. [28855] [43974] [63936] [65157] [65170]

Clomipramine: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

Clozapine: (Major) Avoid coadministration of azithromycin with clozapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Treatment with clozapine has been associated with QT prolongation, TdP, cardiac arrest, and sudden death. [28262] [28855] [43974] [65157] [65170]

Codeine; Phenylephrine; Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974] [55578] [65157] [65170]
**Codeine; Promethazine:** (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974] [55578] [65157] [65170]

**Colchicine:** (Moderate) Caution is warranted with the concomitant use of colchicine and azithromycin as increased colchicine concentrations may occur. Monitor for colchicine toxicity. Colchicine accumulation may be greater in patients with renal or hepatic impairment. Coadministration with azithromycin resulted in an increase in colchicine Cmax of 21.6% and an increase in the AUC of 57.1%. [36114]

**Colchicine; Probenecid:** (Moderate) Caution is warranted with the concomitant use of colchicine and azithromycin as increased colchicine concentrations may occur. Monitor for colchicine toxicity. Colchicine accumulation may be greater in patients with renal or hepatic impairment. Coadministration with azithromycin resulted in an increase in colchicine Cmax of 21.6% and an increase in the AUC of 57.1%. [36114]

**Conjugated Estrogens; Bazedoxifene:** (Moderate) Coadministration of azithromycin and bazedoxifene increased the Cmax of bazedoxifene by 6% and decreased AUC of bazedoxifene by 15%. The clinical effect of these changes is not described. [56074]

**Crizotinib:** (Major) Avoid coadministration of crizotinib with azithromycin due to the risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib if QT prolongation occurs. Crizotinib has been associated with concentration-dependent QT prolongation. Prolongation of the QT interval and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28855] [43974] [45458] [65157] [65170]

**Cyclosporine:** (Moderate) Caution is warranted with the concomitant use of azithromycin and cyclosporine as increased cyclosporine concentrations may occur. Dose adjustment of cyclosporine may be necessary; monitor cyclosporine serum concentrations during use with azithromycin and after discontinuation of azithromycin. [28404]

**Dasatinib:** (Major) Avoid coadministration of azithromycin with dasatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. In vitro studies have shown that dasatinib has the potential to prolong cardiac ventricular repolarization (prolong QT interval). [28855] [32387] [43974] [65157] [65170]

**Degarelix:** (Major) Avoid coadministration of azithromycin with degarelix due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Androgen deprivation therapy (i.e., degarelix) may prolong the QT/QTc interval. [28855] [46869] [65157] [65170]

**Desflurane:** (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]

**Desipramine:** (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

**Deutetrabenazine:** (Major) Avoid coadministration of azithromycin with deutetrabenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. For patients taking a deutetrabenazine dosage more than 24 mg/day with azithromycin, assess the QTc interval before and after increasing the dosage of either medication. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Clinically relevant QTc prolongation may occur with deutetrabenazine. [28855] [43974] [61845] [65157] [65170]

**Dextromethorphan; Promethazine:** (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974] [55578] [65157] [65170]

**Dextromethorphan; Quinidine:** (Major) Avoid coadministration of azithromycin with quinidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Quinidine administration is associated with QT prolongation and TdP. [28855] [42280] [43974] [47357] [65157] [65170]

**Dienogest; Estradiol valerate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Digoxin:** (Moderate) Monitor digoxin concentrations before and during concomitant use of azithromycin and reduce the digoxin dose if necessary. Elevated digoxin concentrations have been observed when azithromycin has been coadministered with digoxin. [28272] [29743]

**Dihydroergotamine:** (Minor) Carefully monitor patients when azithromycin and dihydroergotamine are used concomitantly. Pharmacokinetic and/or pharmacodynamic interactions with dihydroergotamine have been observed with other macrolides. [28858] [34473]

**Disopyramide:** (Major) Avoid coadministration of azithromycin with disopyramide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte...
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Disopyramide is associated with QT prolongation and TdP. [28228] [28855] [43974] [65170]

Dofetilide: (Major) Avoid coadministration of azithromycin with dofetilide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Dofetilide, a Class III antiarrhythmic agent, is associated with a well-established risk of QT prolongation and TdP. [28221] [28432] [28457] [28855] [43974] [65170] [65170]

Dolasetron: (Major) Avoid coadministration of azithromycin with dolasetron due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Dolasetron has been associated with a dose-dependent prolongation in the QT, PR, and QRS intervals on an electrocardiogram. [28855] [42844] [43974] [65157] [65170]

Dolutegravir; Rilpivirine: (Major) Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28855] [43974] [44376] [65157] [65170]

Donepezil: (Major) Avoid coadministration of azithromycin with donepezil due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy. [28855] [43974] [59321] [59322] [65170] [65170]

Donepezil; Memantine: (Major) Avoid coadministration of azithromycin with donepezil due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy. [28855] [43974] [59321] [59322] [65170] [65170]

Doxepin: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65170] [65170]

Dronedarone: (Severe) Coadministration of dronedarone and azithromycin is contraindicated due to the potential for QT prolongation and torsade de pointes (TdP). There have been case reports of QT prolongation and TdP with the use of azithromycin in post-marketing reports. Dronedarone administration is associated with a dose-related increase in the QTc interval. The increase in QTc is approximately 10 milliseconds at doses of 400 mg twice daily (the FDA-approved dose) and up to 25 milliseconds at doses of 1600 mg twice daily. Although there are no studies examining the effects of dronedarone in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. [28855] [36101] [43974]

Droperidol: (Major) Avoid coadministration of azithromycin with droperidol due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances.
imbalances. Initiate droperidol at a low dose and increase the dose as needed to achieve the desired effect. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Droperidol administration is associated with an established risk for QT prolongation and TdP. Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal. [28235] [28236] [28237] [28855] [43974] [51289] [65157] [65170]

**Drospirenone:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetracyclines, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Drospirenone: Estradiol:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracyclines did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Drospirenone: Ethinyl Estradiol:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracyclines did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Drospirenone; Ethinyl Estradiol; Levomefolate: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Efavirenz: (Major) Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QTc prolongation has been observed with the use of efavirenz. [28442] [28855] [43974] [65157] [65170]

Efavirenz; Emtricitabine; Tenofovir: (Major) Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QTc prolongation has been observed with the use of efavirenz. [28442] [28855] [43974] [65157] [65170]

Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QTc prolongation has been observed with the use of efavirenz. [28442] [28855] [43974] [65157] [65170]

Eliglustat: (Major) Avoid coadministration of azithromycin with eliglustat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Eliglustat is predicted to cause PR, QRS, and/or QT prolongation at significantly elevated plasma concentrations. [28855] [43974] [57803] [65157] [65170]
Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the

Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the

Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the

Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the

Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the

Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Estradiol; Norethindrone: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Estradiol; Norgestimate: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Ethinyl Estradiol: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tamafoxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Desogestrel:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tamafoxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Ethynodiol Diacetate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tamafoxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Etonogestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Ethinyl Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Ethinyl Estradiol; Levonorgestrel; Ferrous bisglycinate: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]
contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Norelgestromin:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Norethindrone Acetate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true
incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Norethindrone; Ferrous fumarate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]
significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Norgestimate:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacín, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ethinyl Estradiol; Norgestrel:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacín, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Ezogabine:** (Major) Avoid coadministration of azithromycin with ezogabine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ezogabine has been associated with QT prolongation. [28855] [43974] [44800] [65157] [65170]
**Fingolimod:** (Major) Avoid coadministration of azithromycin with fingolimod due to the increased risk of QT prolongation. If concomitant use is unavoidable, overnight monitoring with continuous ECG in a medical facility is advised after the first dose of fingolimod; monitor ECG closely throughout therapy, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Fingolimod initiation results in decreased heart rate and may prolong the QT interval. Fingolimod has not been studied in patients treated with drugs that prolong the QT interval, but drugs that prolong the QT interval have been associated with cases of TdP in patients with bradycardia. [28855] [41823] [43974] [65157] [65170]

**Flecainide:** (Major) Avoid coadministration of azithromycin with flecainide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Flecainide is a Class IC antiarrhythmic and is also associated with a possible risk for QT prolongation and/or TdP; flecainide increases the QT interval, but largely due to prolongation of the QRS interval. Although causality for TdP has not been established for flecainide, patients receiving concurrent drugs which have the potential for QT prolongation, such as azithromycin, may have an increased risk of developing proarrhythmias. [23774] [28752] [28855] [43974] [65157] [65170]

**Fluconazole:** (Major) Avoid coadministration of azithromycin with fluconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Fluconazole has been associated with QT prolongation and rare cases of TdP. [28674] [28855] [43974] [65157] [65170]

**Fluoxetine:** (Major) Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation and TdP have been reported in patients treated with fluoxetine. [28855] [32127] [43974] [65157] [65170]

**Fluoxetine; Olanzapine:** (Major) Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation and TdP have been reported in patients treated with fluoxetine. [28855] [32127] [43974] [65157] [65170] (Major) Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28785] [28855] [32732] [32734] [32745] [32746] [43974] [65157] [65170]

**Fluphenazine:** (Major) Avoid coadministration of azithromycin with fluphenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Fluphenazine is associated with a possible risk for QT prolongation. Theoretically, fluphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. [28514] [28855] [43974] [65157] [65170]

**Fluticasone; Salmeterol:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct...
Electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Fluticasone: Umeclidinium; Vilanterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Fluticasone: Vilanterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Fluvoxamine: (Major) Avoid coadministration of azithromycin with fluvoxamine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation and TdP have been reported during fluvoxamine postmarketing use. [28855] [50507] [65157] [65170]

Formoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Formoterol: Mometasone: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Flucarbazone: (Major) Avoid coadministration of azithromycin with foscarnet due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Foscarnet: (Major) Avoid coadministration of azithromycin with foscarnet due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]
postmarketing surveillance. Both QT prolongation and TdP have been reported during postmarketing use of foscarnet. [28377] [28855] [43974] [65157] [65170]

**Fosphenytoin**: (Minor) Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with fosphenytoin. Azithromycin was not implicated in clinical trials with drug interactions with fosphenytoin. However, specific drug interaction studies have not been performed with the combination of azithromycin and fosphenytoin. [28855]

**Gemifloxacin**: (Major) Avoid coadministration of azithromycin with gemifloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Gemifloxacin may also prolong the QT interval in some patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin. The likelihood of QTc prolongation may increase with increasing dose of the drug; therefore, the recommended dose should not be exceeded especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher. [28419] [28420] [28424] [28855] [43974] [65157] [65170]

**Gemtuzumab Ozogamicin**: (Major) Avoid coadministration of azithromycin with gemtuzumab due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. [28855] [43974] [62292] [65157] [65170]

**Gilteritinib**: (Major) Avoid coadministration of azithromycin with gilteritinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Gilteritinib has been associated with QT prolongation. [28855] [43974] [63787] [65157] [65170]

**Glasdegib**: (Major) Avoid coadministration of azithromycin with glasdegib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia. [28855] [43974] [63777] [65157] [65170]

**Glycopyrrolate; Formoterol**: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Goserelin**: (Major) Avoid coadministration of azithromycin with goserelin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28592] [28855] [43974] [65157] [65170]

**Granisetron**: (Major) Avoid coadministration of azithromycin with granisetron due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Granisetron may prolong the QT interval, especially in patients with bradycardia. [28855] [43974] [65157] [65170]
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Granisetron has been associated with QT prolongation. [28855] [31723] [43974] [65157] [65170]

**Halogenated Anesthetics:** (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Excessive doses (particularly in the overdose setting) or IV administration of haloperidol may be associated with a higher risk of QT prolongation. [23500] [23779] [28225] [28307] [28415] [28416] [28855] [43974] [65157] [65170]

**Haloperidol:** (Major) Avoid coadministration of azithromycin with haloperidol due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]

**Halothane:** (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]

**Histrelin:** (Major) Avoid coadministration of azithromycin with histrelin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [30369] [43974] [65157] [65170]

**Hydroxychloroquine:** (Major) Avoid coadministration of hydroxychloroquine and azithromycin due the risk of additive QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances (See Therapeutic Drug Monitoring for recommendations specific to COVID-19). Hydroxychloroquine prolongs the QT interval. QT prolongation and torsade de pointe (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28855] [41806] [43974] [65157] [65170]

**Hydroxyzine:** (Major) Avoid coadministration of azithromycin with hydroxyzine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Postmarketing data indicate that hydroxyzine causes QT prolongation and TdP. [28855] [43974] [47129] [65157] [65170]

**Ibutilide:** (Major) Avoid coadministration of azithromycin with ibutilide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated. The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. [28855] [41830] [43974] [65157] [65170]

**Iloperidone:** (Major) Avoid coadministration of azithromycin with iloperidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Granisetron has been associated with QT prolongation. [28855] [31723] [43974] [65157] [65170]
Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28855] [36146] [43974] [65157] [65170]

**Imipramine:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Indacaterol; Glycopyrrolate:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Inotuzumab Ozogamicin:** (Major) Avoid coadministration of inotuzumab ozogamicin with azithromycin due to the potential for additive QT interval prolongation and risk of torsade de pointes (TdP). If coadministration is unavoidable, obtain an ECG and serum electrolytes prior to the start of treatment, after treatment initiation, and periodically during treatment. Avoid any non-essential QT prolonging drugs and correct electrolyte imbalances. Inotuzumab has been associated with QT interval prolongation. QT prolongation and TdP have been spontaneously reported during azithromycin postmarketing surveillance. [28855] [43974] [62245] [65157] [65170]

**Isoflurane:** (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]

**Itraconazole:** (Major) Avoid coadministration of azithromycin with itraconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Itraconazole has been associated with prolongation of the QT interval. [28855] [40233] [43974] [57441] [65157] [65170]

**Ivosidenib:** (Major) Avoid coadministration of azithromycin withivosidenib due to an increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib.
QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28855] [43974] [63368] [65157] [65170]

**Ketoconazole:** (Major) Avoid coadministration of azithromycin with ketoconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ketoconazole has been associated with prolongation of the QT interval. [27982] [28855] [43974] [65157] [65170]

**Lapatinib:** (Major) Avoid coadministration of azithromycin with lapatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and TdP have been reported in postmarketing experience with lapatinib. [28855] [33192] [43974] [65157] [65170]

**Lefamulin:** (Major) Avoid coadministration of azithromycin with lefamulin as concurrent use may increase the risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac conduction is unknown. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28855] [43974] [64576] [65157] [65170]

**Lenvatinib:** (Major) Avoid coadministration of azithromycin with lenvatinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Prolongation of the QT interval has been reported with lenvatinib therapy. [28855] [43974] [58782] [65157] [65170]

**Leuprolide:** (Major) Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [43800] [43974] [65157] [65170]

**Leuprolide: Norethindrone:** (Major) Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [43800] [43974] [65157] [65170] (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Levalbuterol**: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]

**Levofloxacin**: (Major) Avoid coadministration of azithromycin with levofloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Levofloxacin has been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. [28421] [28855] [43974] [65157] [65170]

**Levonorgestrel**: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tafamoxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Lithium**: (Major) Avoid coadministration of azithromycin with lithium due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Lithium has also been associated with QT prolongation. [28855] [43974] [59809] [59810] [59811] [65157] [65170]

**Lofexidine**: (Major) Avoid coadministration of azithromycin with lofexidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Lofexidine prolongs the QT interval. [28855] [43974] [63161] [65157] [65170]
**Long-acting beta-agonists:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Loperamide:** (Major) Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. [28855] [30106] [43974] [60864] [65157] [65170]

**Loperamide; Simethicone:** (Major) Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. [28855] [30106] [43974] [60864] [65157] [65170]

**Lopinavir; Ritonavir:** (Major) Avoid coadministration of azithromycin with lopinavir; ritonavir due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Lopinavir; ritonavir is associated with QT prolongation. [28341] [28855] [43974] [65157] [65170]

**Macimorelin:** (Major) Avoid coadministration of azithromycin with macimorelin due to the increased risk of QT prolongation and torsade de pointes-type ventricular tachycardia. Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin is recommended. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Treatment with macimorelin has been associated with an increase in the corrected QT (QTc) interval. [28855] [43974] [62723] [65150] [65157] [65170]

**Magnesium Hydroxide:** (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]

**Maprotiline:** (Major) Avoid coadministration of azithromycin with maprotiline due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation. Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. [28759] [28855] [43974] [65157] [65170]
Mefloquine: (Major) Avoid coadministration of azithromycin with mefloquine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. [28301] [28855] [43974] [65157] [65170]

Meperidine; Promethazine: (Major) Avoid coadministration of azithromycin with meperidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974] [55578] [65157] [65170]

Mestranol; Norethindrone: (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetracyclines, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

Metaproterenol: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]

Methadone: (Major) Avoid coadministration of azithromycin with methadone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Methadone is considered to be associated with an increased risk for QT prolongation and TdP, especially at higher doses (more than 200 mg/day but averaging approximately 400 mg/day in adult patients). Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. [28319] [28320] [28321] [28322] [28855] [33136] [43974] [65157] [65170]

Metronidazole: (Major) Avoid coadministration of azithromycin with metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances.
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Potential QT prolongation has been reported in limited case reports with metronidazole. [28855] [43974] [57377] [57378] [65157] [65170]

**Midostaurin:** (Major) Avoid coadministration of azithromycin with midostaurin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation was reported in patients who received midostaurin in clinical trials. [28855] [43974] [61906] [65157] [65170]

**Mifepristone:** (Major) Avoid coadministration of azithromycin with mifepristone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Mifepristone has been associated with dose-dependent prolongation of the QT interval. [28855] [43974] [48697] [65157] [65170]

**Mirtazapine:** (Major) Avoid coadministration of azithromycin with mirtazapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Mirtazapine has been associated with dose-dependent prolongation of the QT interval. TdP has been reported postmarketing, primarily in overdose or in patients with other risk factors for QT prolongation. [28855] [40942] [43974] [65157] [65170]

**Moxifloxacin:** (Major) Avoid coadministration of azithromycin with moxifloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Quinolones have been associated with a risk of QT prolongation. Although extremely rare, TdP has been reported during postmarketing surveillance of moxifloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. [28423] [28855] [43974] [65157] [65170]

**Nelfinavir:** (Moderate) Coadministration of nelfinavir and azithromycin results in increased azithromycin concentrations. Dosage adjustments are not necessary, although patients should be monitored for azithromycin related adverse effects such as increased hepatic enzymes and hearing impairment. [28839] [34329]

**Nilotinib:** (Major) Avoid coadministration of azithromycin with nilotinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Sudden death and QT prolongation have been reported in patients who received nilotinib therapy. [28855] [43974] [58766] [65157] [65170]

**Norethindrone:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetracyclin, and tetracycline did not alter plasma concentrations of OCs. Antituberculosis drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma...
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be underreported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Norgestrel:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetaflexacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be underreported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Nortriptyline:** (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

**Octreotide:** (Major) Avoid coadministration of azithromycin with octreotide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval. [28432] [28855] [29113] [30624] [43974] [65157] [65170]

**Ofloxacin:** (Major) Avoid coadministration of azithromycin with ofloxacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Quinolones have been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. [28855] [30738] [43974] [65157] [65170]

**Olanzapine:** (Major) Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine...
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28785] [28855] [32732] [32734] [32745] [32746] [43974] [65157] [65170]

**Olodaterol:** (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonsists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonsists as compared to short-acting beta-agonsists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

**Ondansetron:** (Major) Avoid coadministration of azithromycin with ondansetron due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ondansetron has been associated with a dose-related increase in the QT interval and postmarketing reports of TdP. [28855] [31266] [32722] [43974] [65157] [65170]

**Oral Contraceptives:** (Moderate) It would be prudent to recommend alternative or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, tetracycline, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with these data, but noted that individual patients have been identified who experienced significant decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., patches, rings) are not available. [28482] [28509]

**Osimertinib:** (Major) Avoid coadministration of azithromycin with osimertinib if possible due to the risk of QT prolongation and torsade de pointes (TdP). If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of osimertinib therapy with dose reduction or discontinuation may be necessary if QT prolongation occurs. QT prolongation and TdP have been spontaneously reported during azithromycin postmarketing surveillance. Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. [28855] [43974] [60297] [65157] [65170]

**Oxaliplatin:** (Major) Avoid coadministration of azithromycin with oxaliplatin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation and ventricular arrhythmias including fatal TdP have been reported with oxaliplatin use in postmarketing experience. [28855] [41958] [43974] [65157] [65170]

https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&type=0&printSections=monindi&printSections=monsup&printSections=mo
Paliperidone: (Major) Avoid coadministration of azithromycin with paliperidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Paliperidone has been associated with QT prolongation; torsade de pointes and ventricular fibrillation have been reported in the setting of overdose. [28855] [40936] [43974] [65157] [65170]

Panobinostat: (Major) Avoid coadministration of azithromycin with panobinostat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation has been reported with panobinostat. [28855] [43974] [58821] [65157] [65170]

Pasireotide: (Major) Avoid coadministration of azithromycin with pasireotide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT prolongation has also occurred with pasireotide at therapeutic and supra-therapeutic doses. [28855] [43974] [52611] [65157] [65170]

Pazopanib: (Major) Avoid coadministration of azithromycin with pazopanib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Pazopanib has been reported to prolong the QT interval. [28855] [37098] [43974] [65157] [65170]

Pentamidine: (Major) Avoid coadministration of azithromycin with pentamidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Systemic pentamidine has been associated with QT prolongation. [23620] [23778] [28419] [28855] [28879] [43974] [65157] [65170]

Perphenazine: (Major) Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. [28415] [28855] [43974] [65157] [65170]

Perphenazine: Amitriptyline: (Major) Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. [28415] [28855] [43974] [65157] [65170] (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Phenylephrine: Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974] [55578] [65157] [65170]

Phenytoin: (Minor) Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with phenytoin. Azithromycin was not implicated in clinical trials with drug interactions with phenytoin. However, specific drug interaction studies have not been performed with the combination of azithromycin and phenytoin. [28855]

Pimavanserin: (Major) Avoid coadministration of azithromycin with pimavanserin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Pimavanserin prolongs the QT interval. [28855] [43974] [60748] [65157] [65170]

Pimozide: (Severe) Pimozide is associated with a well-established risk of QT prolongation and torsade de pointes (TdP). Because of the potential for TdP, use of macrolide antibiotics with pimozide is contraindicated. [28225] [28855] [43258] [43463] [59321]

Pirbuterol: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]

Pitolisant: (Major) Avoid coadministration of azithromycin with pitolisant due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Pitolisant prolongs the QT interval. [28855] [43974] [64562] [65157] [65170]

Posaconazole: (Major) Avoid coadministration of azithromycin with posaconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Posaconazole has been associated with prolongation of the QT interval as well as rare cases of TdP. [28855] [32723] [43974] [65157] [65170]

Pravastatin: (Moderate) Azithromycin has the potential to increase pravastatin exposure when used concomitantly. Coadminister pravastatin and azithromycin cautiously due to a potential increased risk of myopathies. [45507]

Primaquine: (Major) Avoid coadministration of azithromycin with primaquine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Primaquine has the potential for QT interval prolongation. [28855] [41984] [43974] [65157] [65170]

Procainamide: (Major) Avoid coadministration of azithromycin with procainamide due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Procainamide has the potential for QT prolongation. [28855] [43974] [55578] [65157] [65170]
postmarketing surveillance. Procainamide is associated with a well-established risk of QT prolongation and TdP. [28250] [28855] [43974] [65157] [65170]

**Prochlorperazine:** (Major) Avoid coadministration of azithromycin with prochlorperazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. [28415] [28855] [43974] [65157] [65170]

**Promethazine:** (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974] [55578] [65157] [65170]

**Propafenone:** (Major) Avoid coadministration of azithromycin with propafenone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Propafenone is a Class IC antiarrhythmic which increases the QT interval, but largely due to prolongation of the QRS interval. [28287] [28855] [43974] [65157] [65170]

**Protriptyline:** (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

**Quetiapine:** (Major) Avoid coadministration of azithromycin with quetiapine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Limited data, including some case reports, suggest that quetiapine may be associated with a significant prolongation of the QTc interval in rare instances. [28855] [29118] [33068] [33072] [33074] [43974] [65157] [65170]

**Quinidine:** (Major) Avoid coadministration of azithromycin with quinidine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Quinidine administration is associated with QT prolongation and TdP. [28855] [42280] [43974] [47357] [65157] [65170]

**Quinine:** (Major) Avoid coadministration of azithromycin with quinine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Quinidine has been associated with QT prolongation and rare cases of TdP. [28855] [31403] [43974] [65157] [65170]

**Ranolazine:** (Major) Avoid coadministration of azithromycin with ranolazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte...
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval. Although there are no studies examining the effects of ranolazine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. [28855] [31938] [43974] [65157] [65170]

Ribociclib: (Major) Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption. [28855] [43974] [61816] [65157] [65170]

Ribociclib; Letrozole: (Major) Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption. [28855] [43974] [61816] [65157] [65170]

Rilpivirine: (Major) Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28855] [43974] [44376] [65157] [65170]

Risperidone: (Major) Avoid coadministration of azithromycin with risperidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Risperidone has been associated with a possible risk for QT prolongation and/or TdP, primarily in the overdose setting. [28225] [28414] [28416] [28855] [43974] [65157] [65170]

Romidepsin: (Major) Avoid coadministration of azithromycin with romidepsin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Romidepsin has been reported to prolong the QT interval. [28855] [37292] [43974] [65157] [65170]

Salmeterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Saquinavir: (Major) Avoid coadministration of azithromycin with saquinavir boosted with ritonavir due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Saquinavir boosted with ritonavir increases the QT interval in a dose-
dependent fashion, which may increase the risk for serious arrhythmias such as TdP. [28855] [28995] [43974] [65157] [65170]

Sevoflurane: (Major) Avoid coadministration of azithromycin with sevoflurane due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Sevoflurane's FDA-approved labeling recommends avoiding concomitant use with drugs known to prolong the QTc interval; however, the risk of sevoflurane-induced QT prolongation is generally considered to be low in clinical practice. Its effect on QTc interval is minimal (typically less than 5 msec), and the drug has been used safely in patients with cardiac disease (e.g., recent myocardial infarction, unstable angina, chronic heart failure). [28343] [28855] [43974] [64391] [64392] [64394] [64395] [64396] [65157] [65170]

Siponimod: (Major) Avoid coadministration of azithromycin with siponimod due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Siponimod therapy prolonged the QT interval at recommended doses in a clinical study. [28855] [43974] [64031] [65157] [65170] [65170]

Sertraline: (Major) Avoid coadministration of azithromycin with sertraline due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Sertraline's FDA-approved labeling recommends avoiding concomitant use with drugs known to prolong the QTc interval; however, the risk of sertraline-induced QT prolongation is generally considered to be low in clinical practice. Its effect on QTc interval is minimal (typically less than 5 msec), and the drug has been used safely in patients with cardiac disease (e.g., recent myocardial infarction, unstable angina, chronic heart failure). [28343] [28855] [43974] [65157] [65170]
Sodium picosulfate; Magnesium oxide; Anhydrous citric acid: (Major) Prior or concomitant use of antibiotics with sodium picosulfate; magnesium oxide; anhydrous citric acid may reduce efficacy of the bowel preparation as conversion of sodium picosulfate to its active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM) is mediated by colonic bacteria. If possible, avoid coadministration. Certain antibiotics (i.e., tetracyclines and quinolones) may chelate with the magnesium in sodium picosulfate; magnesium oxide; anhydrous citric acid solution. Therefore, these antibiotics should be taken at least 2 hours before and not less than 6 hours after the administration of sodium picosulfate; magnesium oxide; anhydrous citric acid solution. [51258]

Solifenacin: (Major) Avoid coadministration of azithromycin with solifenacin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Solifenacin has been associated with dose-dependent prolongation of the QT interval. TdP has been reported with postmarketing use, although causality was not determined. [28855] [30515] [43974] [65157] [65170]

Sorafenib: (Major) Avoid coadministration of azithromycin with sorafenib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption or discontinuation of sorafenib therapy may be necessary if QT prolongation occurs. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Sorafenib has been associated with QT prolongation. [28855] [31832] [43974] [65157] [65170]

Sotolol: (Major) Avoid coadministration of azithromycin with sotalol due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Sotalol administration is associated with QT prolongation and TdP. Proarrhythmic events should be anticipated after initiation of therapy and after each upward dosage adjustment. [28234] [28855] [43974] [65157] [65170]

Sunitinib: (Major) Avoid coadministration of azithromycin with sunitinib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Sunitinib can cause dose-dependent QT prolongation, which may increase the risk for ventricular arrhythmias, including TdP. [28855] [31970] [43974] [65157] [65170]

Tacrolimus: (Major) Avoid coadministration of azithromycin with tacrolimus due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Tacrolimus may prolong the QT interval and cause TdP. [27353] [27354] [28225] [28855] [43974] [65157] [65170]

Talazoparib: (Moderate) Monitor for an increase in talazoparib-related adverse reactions if coadministration with azithromycin is necessary. In clinical trials, coadministration with azithromycin increased talazoparib exposure by approximately 8%. [63651]

Tamoxifen: (Major) Avoid coadministration of azithromycin with tamoxifen due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses. Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses. [28855] [43974] [61870] [61871] [61872] [63589] [65157] [65170]

Telavancin: (Major) Avoid coadministration of azithromycin with telavancin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine...
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Telormifene has been associated with QT prolongation. [28855] [36615] [43974] [65157]
[65170]

Telorphomycin: (Major) Avoid coadministration of azithromycin with telorphomycin due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Telorphomycin is also associated with QT prolongation and TdP. [28156] [28855] [43974]
[65157] [65170]

Terbutaline: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to
short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]

Tetrabenazine: (Major) Avoid coadministration of azithromycin with tetrabenazine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Tetrabenazine causes a small increase in the corrected QT interval (QTc). [28855] [34389]
[43974] [65157] [65170]

Thioridazine: (Severe) Coadministration of thioridazine and azithromycin is contraindicated due to an increased risk
of QT prolongation. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during
azithromycin postmarketing surveillance. Thioridazine is associated with a well-established risk of QT prolongation
and TdP. [28225] [28293] [28855] [43974]

Tiotropium; Olodaterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710]
[65157] [65170]

Tolterodine: (Major) Avoid coadministration of azithromycin with tolterodine due to the increased risk of QT
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Tolterodine has been associated with dose-dependent prolongation of the QT interval,
especially in poor CYP2D6 metabolizers. [28855] [31112] [43974] [65157] [65170]

Toremifene: (Major) Avoid coadministration of azithromycin with toremifene if possible due to the risk of additive
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte
imbbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin
postmarketing surveillance. Toremifene has been shown to prolong the QTc interval in a dose- and concentration-
related manner. [28822] [28855] [43974] [65157] [65170]
Trazodone: (Major) Avoid coadministration of azithromycin with trazodone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Trazodone can prolong the QT/QTc interval at therapeutic doses. In addition, there are postmarketing reports of TdP. [28855] [43974] [65157] [65170]

Tricyclic antidepressants: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

Trifluoperazine: (Major) Avoid coadministration of azithromycin with trifluoperazine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Trifluoperazine is associated with a possible risk for QT prolongation. Theoretically, trifluoperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. [28415] [28855] [43974] [65157] [65170]

Trimipramine: (Major) Avoid coadministration of azithromycin with trimipramine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]

Triptorelin: (Major) Avoid coadministration of azithromycin with triptorelin due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [43974] [45411] [65157] [65170]

Umeclidinium; Vilanterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]

Vandetanib: (Major) Avoid coadministration of azithromycin with vandetanib due to an increased risk of QT prolongation and torsade de pointes (TdP). If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of vandetanib therapy or dose reduction may be necessary for QT prolongation. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Vandetanib can prolong the QT interval in a concentration-dependent manner; TdP and sudden death have been reported in patients receiving vandetanib. [28855] [43901] [43974] [65157] [65170]
**Vardenafil:** (Major) Avoid coadministration of azithromycin with vardenafil due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Both therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval. [28216] [28855] [41124] [43974] [65157] [65170]

**Vemurafenib:** (Major) Avoid coadministration of azithromycin with vemurafenib due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Vemurafenib has been associated with QT prolongation. [28855] [43974] [45335] [65157] [65170]

**Venlafaxine:** (Major) Avoid coadministration of azithromycin with venlafaxine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Venlafaxine administration is associated with a possible risk of QT prolongation; TdP has reported with postmarketing use. [28855] [33715] [43974] [65157] [65170]

**Voriconazole:** (Major) Avoid coadministration of azithromycin with voriconazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Voriconazole has been associated with prolongation of the QT interval and rare cases of arrhythmias, including TdP. [28158] [28855] [43974] [65157] [65170]

**Vorinostat:** (Major) Avoid coadministration of azithromycin with vorinostat due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Vorinostat is associated with a risk of QT prolongation. [28855] [32789] [43974] [65157] [65170]

**Warfarin:** (Moderate) Carefully monitor the PT/INR in patients who receive warfarin and azithromycin concomitantly. Postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin. [23809] [28855]

**Ziprasidone:** (Major) Avoid coadministration of azithromycin with ziprasidone due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of TdP in patients with multiple confounding factors. [28233] [28855] [43974] [65157] [65170]

Revision Date: 04/14/2020 02:26:00 AM

**References**


28262 – Clozaril (clozapine) tablets package insert. Rosemont, PA: HLS Therapeutics (USA), Inc. (Clozaril is a registered trademark of Novartis AG); 2017 Feb.


28407 – Propulsid (cisapride) package insert. Titusville, NJ: Janssen Pharmaceutical; 2006 Oct. NOTE: As of May 2000; Propulsid has only been available in the United States via an investigational limited access program to ensure proper patient screening and prescribing.


28592 – Zoladex (goserelin acetate 3.6 mg implant) package insert. Lake Forest, IL: TerSera Therapeutics LLC; 2019 Feb.


48869 – Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and tosade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011;120:103-10.


57094 – ZyCAD (ceritinib) package insert. Indianapolis, IN: Novartis; 2019 March.


57803 – Cerdelga (eliglustat) capsules. Waterford, Ireland: Genzyme Ireland, Ltd.; 2018 Sept.


Monitoring Parameters

- ECG
- LFTs

IV Compatibility of Azithromycin with:

Legend

- **C** = Compatible
- **I** = Incompatible
- **△** = Results uncertain, variable or dependent on conditions
- **ND** = No Data Available

From Trissel's 2™ Clinical Pharmaceutics Database

<table>
<thead>
<tr>
<th>Drug</th>
<th>Admixture</th>
<th>Syringe</th>
<th>Y-Site Administration</th>
<th>For Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir sodium</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Alatrofloxacin mesylate</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Alemtuzumab</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Alfentanil hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Amikacin sulfate</td>
<td>ND</td>
<td>ND</td>
<td><strong>△</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Aminocaproic acid</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Aminophylline</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Amiodarone hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td><strong>I</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Amphotericin B conventional colloidal</td>
<td>ND</td>
<td>ND</td>
<td><strong>I</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Amphotericin B lipid complex (Abelcet)</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Amphotericin B liposome (Ambisome)</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Ampicillin sodium</td>
<td>ND</td>
<td>ND</td>
<td><strong>C</strong></td>
<td>ND</td>
</tr>
<tr>
<td>Admixture</td>
<td>Syringe</td>
<td>Y-Site Administration</td>
<td>For Dilution</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>-----------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Ampicillin sodium-sulbactam sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Anidulafungin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Argatroban</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Asparaginase</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Atenolol</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Atracurium besylate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Aztreonam</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Bleomycin sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Bumetanide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Buprenorphine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Butorphanol tartrate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Calcium gluconate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Carmustine</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Caspofungin acetate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefazolin sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefepime hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefoperazone</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefotetan disodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftaroline fosamil</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftazidime (L-arginine)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftizoxime</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftobiprole medocaril</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftolozane; Tazobactam</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ceftriaxone sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Admixture</td>
<td>Syringe</td>
<td>Y-Site Administration</td>
<td>For Dilution</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------</td>
<td>---------</td>
<td>------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cimetidine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cisatracurium besylate</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Clindamycin phosphate</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cloxacillin sodium</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Cytarabine</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>D5W-Dextrose 5%</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dacarbazine</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Daunorubicin citrate liposome</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dexamethasone sodium phosphate</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dexametomidine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dextrazoxane</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dextrose 5% in lactated Ringer's</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dextrose 5% in sodium chloride 0.3%</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dextrose 5% in sodium chloride 0.45%</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Diazepam</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Digoxin</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Diltiazem hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Diphenhydramine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dobutamine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dolasetron mesylate</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Dopamine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Doripenem</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Doxacurium chloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride liposomal</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Doxycycline hyclate</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Droperidol</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Enalaprilat</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
<td>ND</td>
</tr>
<tr>
<td>Admixture</td>
<td>Syringe</td>
<td>Y-Site Administration</td>
<td>For Dilution</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Ephedrine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Epinephrine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Epirubicin hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Eptifibatide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ertapenem sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Esmolol hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Etoposide phosphate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Famotidine</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Fenoldopam mesylate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Fentanyl citrate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Foscarnet sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Fosphenytoin sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Furosemide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Gallium nitrate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ganciclovir sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Garenoxacin Mesylate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Gatifloxacin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Gemcitabine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Gemtuzumab ozogamicin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Gentamicin sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Granisetron hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Haloperidol lactate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Heparin sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Hetastarch 6% (Hextend)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone sodium phosphate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone sodium succinate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Hydroxyzine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Idarubicin hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Imipenem-cilastatin sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Inamrinone lactate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Admixture</td>
<td>Syringe</td>
<td>Y-Site Administration</td>
<td>For Dilution</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Irinotecan hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Isavuconazonium Sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Isoproterenol hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Ketorolac tromethamine</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Labetalol hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Lactated Ringer's Injection</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Lepirudin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Leucovorin calcium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Levofoxacin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Levophanol tartrate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Lidocaine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Mannitol</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Mechlorethamine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Meperidine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Meropenem</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Mesna</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Methadone hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Methohexital sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Methotrexate sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Metoclopramide hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Metronidazole</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Midazolam hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Milrinone lactate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Minocycline hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Mitoxantrone hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Mivacurium chloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Morphine sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Mycophenolate mofetil hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Nalbuphine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Naloxone hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Admixture</td>
<td>Syringe</td>
<td>Y-Site Administration</td>
<td>For Dilution</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>---------</td>
<td>------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Nesiritide</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Nicardipine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Nitroprusside sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Normal saline- Sodium chloride 0.9%</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
</tr>
<tr>
<td>Normosol M in dextrose 5%</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
</tr>
<tr>
<td>Normosol R in dextrose 5%</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>☢</td>
</tr>
<tr>
<td>Octreotide acetate</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Ondansetron hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Paclitaxel (solvent/surfactant)</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Palonosetron hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Pamidronate disodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Pancuronium bromide</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Pantoprazole sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Pemetrexed disodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Pentamidine isethionate</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Pentobarbital sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Phenobarbital sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Phenylephrine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Phenytoin sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Piperacillin sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Piperacillin sodium-tazobactam sodium</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Plazomicin</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Potassium acetate</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>☢</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Potassium phosphates</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Procainamide hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Prochlorperazine edisylate</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Promethazine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Propranolol hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
<tr>
<td>Quinupristin-Dalfopristin</td>
<td>ND</td>
<td>ND</td>
<td>🟢</td>
<td>ND</td>
</tr>
</tbody>
</table>

https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=53&type=0&printSections=monindi&printSections=monsup&printSections=mons&printSections=mons&printSections=… 123/139
<table>
<thead>
<tr>
<th>Admixture</th>
<th>Syringe</th>
<th>Y-Site Administration</th>
<th>For Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Remifentanil hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Rocuronium bromide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sodium acetate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sodium chloride 0.45%</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sodium phosphates</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Succinylcholine chloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sufentanil citrate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sulfamethoxazole-trimethoprim</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Tedizolid phosphate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Telavancin hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Teniposide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Thiopental sodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Thiotepa</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Ticarcillin disodium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Ticarcillin disodium-clavulanate potassium</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Tirofiban hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Tobramycin sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>TPN (2-in-1) Total Parenteral Nutrition Admixture</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Trimethobenzamide hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Vancomycin hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Vecuronium bromide</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Verapamil hydrochloride</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>VinCRISTine sulfate</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Zoledronic acid</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>
US Drug Names

- Azasite
- Zithromax
- Zithromax Tri-Pak
- Zithromax Z-Pak
- Zmax

Global Drug names

Argentina

- Arzomicin - (Takeda)
- Azibiotic - (Baliarda)
- Azitral - (Sanitas)
- Azitrogal - (Sant Gall)
- Azitrolabsa - (Labsa)
- Azitrolan - (Lanpharm)
- Azitrona - (Klonal)
- Azitrox - (Lepetit)
- Cetaxim - (TRB)
- Clearsing - (Duncan)
- Cronopen - (Elea)
- Doyle - (Raffo)
- Fabodrox - (Fabop)
- Fabramicina - (Fabra)
- Finatres - (Finadiet)
- Macromax - (Investi)
- Misultina - (Bernabo)
- Naxocina - (AstraZeneca)
- Neblic - (Lazar)
- Nifostin - (Penn)
- Novozitron - (Laboratorio Internacional)
- Orobiotic - (Fortbenton)
- Sitrox - (Biotenk)
- Sumir - (Craveri)
- Talcilina - (Ronnet)
- Tanezox - (Microsules)
- Triamid - (Beta)
- Tritab - (Sidus)
- Tromiatlas - (Atlas)
- Vectocilina - (Panalab)
- Visag - (Poen)
- Zitromax - (Pfizer)

Australia

- Azith - (Alphapharm)
- Zedd - (Medis)
- Zithromax - (Pfizer)
- Zitrocin - (Pfizer)

Austria

- Azyter - (Thea)
- Zithromax - (Pfizer)
Belgium

- Zitromax - (Pfizer)

Brazil

- Astro - (Eurofarma)
- Atromicin - (Teuto)
- Azalide - (Bunker)
- Azatill - (Prodotti)
- Azi - (Sigma)
- Azidromic - (Royton)
- Azimax - (EMS)
- Azimed - (Cimed)
- Azimix - (Ativus)
- Azinostil - (EMS)
- Azitrax - (FARMOQUIMICA)
- Azitrin - (Delta)
- Azitrocin - (Cibran)
- Azitrogran - (Legrand)
- Azitrolab - (Multilab)
- Azitromed - (Medquimica)
- Azitromicil - (Greenpharma)
- Azitromin - (Farmasa)
- Azitron - (Cifarma)
- Azitronax - (Pharlab)
- Azitrophar - (Pharlab)
- Azitrosol - (Luper)
- Azitroxil - (De Mayo)
- Biozitrom - (Biofarma)
- Clindal - (Merck)
- Clindaz - (Merck)
- Ems-Max - (EMS)
- Mac Azi - (Sigma)
- Mazitron - (Uniao Quimica)
- Novatrex - (Ache)
- Selimax - (Libbs)
- Selimax Pulso - (Libbs)
- Siftromin - (Sinterapico)
- Triazi - (Itaca)
- Tromix - (Ariston)
- Tromizir - (Belfar)
- Trozyman - (IQB)
- Zidimax - (Laboris)
- Zimicina - (Sandoz)
- Zitril - (Cazi)
- Zitromax - (Pfizer)
- Zitromil - (GSK)
- Zitroneo - (Neo Quimica)
- Zolprox - (Globo)

Canada

- Zithromax - (Pfizer)
- Zmax - (Pfizer)
- Z-Pak - (Pfizer)
Chile

- Abacten - (Andromaco)
- Asipral - (Labomed)
- Atizor - (Medipharm)
- Azibay - (Bayer)
- Azimit - (Interpharma)
- Azitrom - (Laboratorios Chile)
- Azydrop - (Andromaco)
- Ricilina - (Recalcline)
- Trex - (Saval)
- Zetamax - (Eurofarma)
- Zithromax - (Pfizer)

China

- A Sai Qi - (Yiqiao)
- Ai Mi Qi - (Mei Luo)
- An Mei Qin - (ZhenYuan)
- Ao Li Ping - (Aoya)
- Ba Qi - (Da Heng)
- Bai Ke De Rui - (Bai Ke)
- Bin Qi - (Qi Li)
- BinQi - (Binhu Shuanghe)
- Bo Kang - (Star)
- Chen Yu - (Lukang Chenxin)
- Feng Da Qi - (Asia Pioneer)
- Fu Qi-Hua Yuan - (Jinhui)
- Fu Rui Xin - (Lai En)
- Fuqixing - (Changzheng-Xinkai)
- Fuxin - (Haixin)
- Jin Nuo - (Fenghuang)
- Jin Pai Qi - (Lijun)
- Jinbo - (TianJin)
- Jun Jie - (Lunan)
- Jun Wei Qing - (Tianlong)
- Kai Qi - (Qianjiang)
- Kang Li Jian - (San Lian)
- Kang Qi - (Shunfeng)
- Ke Lin Da - (Liaoyuan Yadong)
- Ke Yan Li - (Liuan Huayuan)
- Kuai Di - (Hayao)
- Kuai Yu - (LuoXin)
- Li Ke Si - (Lai Mei)
- Li Li Kai - (Haishen Liansheng)
- Li Li Xing - (Haishen Liansheng)
- Li Qi - (Yangtze River)
- Lin Bi - (Double-Crane)
- Lipuqi - (Neptunus)
- Lipuxin - (Neptunus)
- Lizhu Qile - (Livzon)
- Lu Jia Kang - (Kanglong)
- Luo Bei Er - (Yong He)
- Luo Qi - (Aida)
- Luoxin Shoukang - (LuoXin)
- Ming Qi Xin - (Mingxin)
- Na Qi - (Pu Luo Kang Yu)
- Pai Fen - (Wanjie High Tech)
- Pai Fu - (Double-Crane)
- Paiqi - (Lijun)
- Pu He - (Chang Fu Jie Jing)
- Pu Le Qi - (Shyndec)
- Pu Yang - (Xin Ma)
- Qi Gu Mei - (Huang Long)
- Qi Hong - (Hayao)
- Qi Mai Xing - (Yatai)
- Qi Nuo - (Double-Crane)
- Qi Tai - (Jiu Tai)
- Qi Xian - (Shenyang First)
- QiLi - (Zhong Bao)
- Qiyue - (Jiqi Huakang)
- Ru Shuang Qi - (Kangliyuan)
- Rui Qi - (GuoRui)
- Rui Qi Lin - (Qian Long)
- Sai Jin Sha - (Tongde)
- Sai Le Xin - (United Lab)
- Sai Qi - (Dade)
- Sheng Nuo Ling - (Sanhome)
- Shepherd - (Ke Lun)
- Shu Luo Kang - (JiChuan)
- Su Shuang - (GuoGuang)
- Sumamed - (Pliva)
- Tailite - (Taiyang)
- Te Li Xin - (Hui Yin Bi)
- Tong Tai Qi Li - (Yi Kang)
- Tuo Neng - (Haixin)
- TuoQi - (Jinfeng)
- Wei Li Qing - (Qingfeng)
- Wei Lu De - (Jianfeng)
- Wei Zong - (Bikang)
- Weihong - (CSPC)
- Xi Le Xin - (Lukang Chenxin)
- Xi Mei - (C & O)
- Xin Da Kang - (Salubris)
- Xin Pu Rui - (Tianlong)
- Ya Rui - (Yatai)
- Yan Sha - (Xibaishou)
- Yi Nuo Da - (ShiJiaZhuang No 4)
- Yi Ou Qing - (Qilu)
- Yi Song - (De Zhou)
- Yi Xin - (Ankehengyi)
- Yin Pei Kang - (Jin Si Li)
- Yong Qi - (Shenlong)
- You Ni Ke - (Tong Yong Tong Meng)
- Yu Qi - (Limin)
- Zaiqi - (Simeere)
- Ze Qi - (Hicin)
- Zithromax - (Pfizer)
- Zithrome - (Hailing)

Czech Republic

- Azibiot - (KRKA)
- Azitrox - (Zentiva)
- Azyter - (Thea)
- Sumamed - (Teva)
- Zetamac - (Pfizer)
- Zitrocin - (Teva)

Denmark
- Azyter - (Thea)
- Zitromax - (Pfizer)

Finland
- Azyter - (Thea)
- Zithromax - (Pfizer)

France
- Azadose - (Pfizer)
- Azyter - (Thea)
- Ordipha - (Tonipharm)
- Zithromax - (Pfizer)

Germany
- Azithro - (Meda)
- Azithrobeta - (Betapharm)
- Azyter - (Thea)
- InfectoAzit - (Infectopharm)
- Ultreon - (Pfizer)
- Zithromax - (Pfizer)

Greece
- Alzirax - (Rafarm)
- Azibactron - (Cross)
- Azibiom - (Chemica)
- Azifarm - (Venifar)
- Azirox - (Pharmanel)
- Azirutech - (Zwitter)
- Azithral - (Cooper (Κοπερ))
- Azithrin - (Alet)
- Azitrolid - (Minerva (Μινερβα))
- Azivir - (Verisfield)
- Azytan - (Medilat)
- Azyter - (Thea)
- Bezanin - (Iasis)
- Binozyt - (Sandoz)
- Ciroz - (Velka)
- Disithrom - (SJA)
- Flumax - (Gerolymatos)
- Goldamycin - (Leon)
- Gramokil - (Santa)
- Novozithron - (Novofarm (Νοβοφαρμ))
- Razimax - (Rafarm)
- Thoraxx - (Alapis)
- Throzimax - (Medilat)
- Zinfect - (Verisfield)
- Zithrobest - (Lyofin)
- Zithro-Due - (Vivax)
- Zithromax - (Pfizer)
- Zithroned - (Euroned)
- Zithropan - (Vocate)
- Zithroplus - (Balu)
- Zithrotel - (Anpharm (Ανφαρμ))
- Zithroxyn - (Help)
- Zitrax - (Genepharm)
- Zyramycin - (Leovan)

Hong Kong

- Athromax - (Quality)
- AZ-1 - (Nidoway)
- AZA - (XL)
- Azee - (Cipla)
- Azibact - (Swedish Trading)
- Azicine - (Stada)
- Azilide - (Yanny Medicines)
- Azimax - (Hovid)
- Azin - (Deltapharm)
- Azinix - (Julius Chen)
- Azirodin - (Julius Chen)
- Azirox - (Sincerity)
- Azaticin - (Wah Kin)
- Azithmax - (Vickmans)
- Azithrocin - (Eugenpharm)
- Azocin - (Eugenpharm)
- Aztrin - (Viewbest)
- Azure - (Eugenpharm)
- Azyter - (Thea)
- Binozyt - (Novartis)
- Clindal AZ - (APT)
- Euzimax - (Vickmans)
- Floctil - (Unison)
- Imexa - (Xepa-Soul Pattinson)
- Marzomax - (Vickmans)
- Nifomax - (Vickmans)
- Qualizith - (Quality)
- Sharozzy - (Pharmasky)
- Sumamed - (Lee)
- Uni-Zitho - (Vickmans)
- Vick-Azithro - (Vickmans)
- Zarom - (Perfect Groups)
- Zathrin - (Star)
- Zetro - (Chariot)
- Zimax - (Unipharm)
- Zimycin - (Star)
- Zith - (Leon)
- Zithrin - (HealthCare PharmaScience)
- Zithromax - (Pfizer)
- Zmax - (Pfizer)
- Zotax - (Hovid)
- Zycin - (Natural Health)

Hungary
- Azi - (Sandoz)
- Azibiot - (KRKA)
- Azicid - (Generics)
- Aziwill - (Goodwill)
- Sumamed - (Teva)
- Zitinn - (Actavis)
- Zitrocin - (Teva)
- Zmax - (Pfizer)

India

- Acex - (Orion)
- Actimycin - (Venus)
- Alicin - (Allenge)
- A-OD - (Elisa)
- Apocin - (Apotex)
- Arcin - (Chemech)
- Arizith - (Arika)
- Arz - (Willow)
- Atm - (Indoco)
- Avzeth - (Positif)
- Az-1 - (Kopran)
- Azard - (Pharma-Tech)
- Azauk - (Aamorb)
- Azbir - (Birz)
- Azee - (Cipla)
- Azegud - (Biosync)
- Azeloc - (Symbiotic)
- Azforin - (Unichem)
- Azibact - (Ipca)
- Azibest - (Blue Cross)
- Azi-Big - (Bestochem)
- Azicip - (Cipla)
- Azicos - (Symbiosis)
- Azicure - (Radicura)
- Azid - (Indi)
- Azidraw - (Q Check)
- Azifast - (Ipca)
- Azifem - (Fem Care)
- Azifine - (Glenmark)
- Azifine - (Glenmark)
- Azigram - (United Lifecare)
- Azikab - (Lancer)
- Azikare - (Ankare)
- Azikil - (Maxo)
- Azileb - (Leben)
- Azilide - (Micro)
- Azilife - (Aqualife)
- Azilin - (Lincoln)
- Azilup - (Lupin)
- Azim - (BL)
- Azimac - (Mandar)
- Azimax - (Cipla)
- Azin - (Indo Pacific)
- Azina - (Zota)
- Azinex - (Aronex)
- Azinix - (Khandelwal)
- Azinova - (Bombay Tablet)
- Azintra - (Intra-Labs)
- Azintra-AX - (Intra-Labs)
- Aziom - (Zenon)
- Azipar - (Molekule)
- Azipokyn - (Misha)
- Azipos - (Aglowmed)
- Aziral - (Hiral)
- Azirid - (Armour)
- Aziriv - (East African)
- Azirock - (Ankom)
- Azis - (Taurus)
- Azisafe - (UniOrange)
- Azisara - (Sarabhai Piramal)
- Aziset - (Active)
- Azisia - (Willow)
- Azison - (Dr Alson)
- Azistar - (Sanifý)
- Azisym - (Symbiosis)
- Azitas - (Intas)
- Aziter - (Gujarat Terce)
- Azith - (Zee)
- Azithom - (Om Biotec)
- Azithral - (Alembic)
- Azithral Jun - (Alembic)
- Azithro - (Ind-Swift)
- Azitone - (Keshav)
- Azitoz - (ATOZ)
- Azitrac - (Invision)
- Azitrin - (Pharmatech)
- Azitrop - (Elfin)
- Azitsa - (Akesiss)
- Azitus - (Zuventus)
- Azivar - (Zota)
- Aziwin - (Bal)
- Aziwok - (Wockhardt)
- Azix - (Alicon)
- Azla - (Candor)
- Azmag - (Magnus)
- Azmic - (Emar)
- Azobac - (Medinova)
- Azolid - (Scoshia)
- Azolife - (Dexter)
- Azom - (Finecure)
- Azomax - (Max)
- Azone - (NB)
- Azopet - (Vista)
- Azostar - (Gentech)
- Azras - (Rass)
- Azrea - (Cinerca)
- Azro - (Abbott)
- Azro AM - (Abbott)
- Aztin - (Laksun)
- Aztus - (Emcure)
- Azvig - (Madhav)
- Azy - (Uniroyal)
- Azylin - (Zota)
- Azysafe - (Overseas)
- Azystate - (Haledew)
- Azyxin - (Centaur)
- Azyxin Plus - (Centaur)
- Azza - (Wintech)
- Bezit - (Plus)
- Bio-AZ - (Biomax)
- Cazita - (Admac)
- Corzi - (DWD)
- Cumycin - (Curex)
- Dazy - (Daksh)
- Elgram - (Captab)
- Elzee - (Elder)
- Ertycin - (Abbott)
- Eszit - (Ester)
- Ezith - (Evershine)
- Flaag - (Flamingo)
- Forit - (Health Care)
- Fydozith - (Xieon)
- Gitro - (Plus)
- G-Thro - (Globus)
- Hizy - (Hos & Ins)
- Infurox - (Servocare)
- Itha - (Alna)
- I-Thro - (Zubit)
- Jocin - (DR Johns)
- Kanny - (Kalpataru)
- Laz - (Hetero)
- Laz-AX - (Hetero)
- Lazith - (Admac)
- Lethro - (Forgo)
- LG-Thral - (Anvik)
- Loromycin - (Novartis)
- L-Thro - (Lexus)
- Macrosafe - (MSN)
- Macrotar - (Torrent)
- Maxazi - (United Biotech)
- Myza - (Esma)
- Nizithro - (Neiss)
- Nodycin - (Nodysis)
- Orflaz Kit - (Aristo)
- Saf Kit - (Biochem)
- Zithrocin - (Biochem)
- Zycin - (Cadila)

Indonesia

- Aziwin - (Aventis)
- Azomax - (Dexa)
- Aztrin - (Pharos)
- Azyter - (Kalbe Vision)
- Binozyt - (Sandoz)
- Ethrimax - (Ethica)
- Maxmor - (Mahakam Beta)
- Mezatrin - (Sanbe)
- Sohomac - (Ethica)
- Trozin - (Tempo Scan Pacific)
- Zarom - (Pyridam)
- Zibramax - (Guardian)
- Zicho - (Nicholas)
- Zifin - (Yarindo)
- Zistic - (Bernofarm)
- Zithrax - (Kalbe)
- Zithromax - (Pfizer)
- Zitrolin - (Otto)
- Zycin - (Interbat)

**Ireland**

- Azromax - (Gerard)
- Azyter - (Thea)
- Zedbac - (Aspire)
- Zithromax - (Pfizer)

**Israel**

- Azenil - (Pfizer)
- Zeto - (Trima)
- Zithromax - (Pfizer)
- Zmax - (Pfizer)

**Italy**

- Azitrocin - (Pfizer)
- Batif - (Epifarma)
- Ribotrex - (Pierre Fabre)
- Trozocina - (Sigma-Tau)
- Zindel - (SoSe)
- Zitrobiotic - (Epifarma)
- Zitromax - (Pfizer)

**Japan**

- Zithromac - (Pfizer)

**Malaysia**

- Azicine - (Stada)
- Azimax - (Hovid)
- Azithro - (M & H)
- Binozyt - (Sandoz)
- Floctil - (Unison)
- Imexa - (Xepa-Soul Pattinson)
- Zithrolide - (Pharmaniaga)
- Zithromax - (Pfizer)
- Zmax - (Pfizer)
- Zynomax - (CCM)

**Mexico**

- Amsati - (Amsa)
- Atoxitom - (Landsteiner)
- Azibiot - (Mavi)
- Azidral - (Silanes)
- Aziphar - (Alpharma)
- Aziteva - (Teva)
- Azitrocin - (Pfizer)
- Azitrohexal - (Sandoz)
- Azo-Max - (Unipharm)
- Azotive - (Aspen)
- Aztrogecin - (Lakeside)
- Charyn - (Wermar)
- Craztronin - (Raam)
- Koptin - (Chinoin)
- Macrozit - (Liomont)
- Marzivag - (Novag)
- Medatz - (Bajamed)
- Mizotryn - (Liferpal)
- Sicalan - (Loeffler)
- Texis - (Atlantis)
- Tromicina - (Offenbach)
- Truxa - (Asofarma)
- Zertalin - (Collins)
- Zithran - (Ranbaxy)
- Zitroflam - (Rimsa)
- Zitroken - (Kendrick)

Netherlands
- Azacleus - (Nucleus)
- Azitro - (Merck)
- Azyter - (Thea)
- Bazyt - (Thea)
- Merckazitro - (Merck)
- Nucaza - (Nucleus)
- Zithromax - (Pfizer)

New Zealand
- Zithromax - (Pfizer)

Norway
- Azitromax - (Pfizer)
- Azyter - (Thea)

Philippines
- Aza-500 - (XL)
- Azeecor - (Akums)
- Azeemycin - (SRS)
- Azemax - (Cathay)
- Azi - (InnoGen)
- Azimax - (Twilight Litaka)
- Azin - (ACME)
- Azithro - (Natrapharm)
- Azithrogen - (Nutramedica)
- Azitrocin - (Mundipharma)
- Azo - (Mediwin)
- Azomycin - (Royale)
- Aztro - (Stallion)
- Azyth - (Sandoz)
- Decantin - (Lok-Beta)
- Geozit - (Geofman)
• Jazit - (Somatec)
• Macromax - (Domesco)
• Macrozith - (Cipla)
• OD Mac - (Farma Iberica)
• Pediazith - (Medlink)
• Romzin - (Biopharma)
• Sitimax - (CSPC)
• Thromaxin - (ACME)
• Trozin - (Mercury)
• Wiltrozin - (Hizon)
• Zenith - (Pediatractiva)
• Zithran - (Lloyd)
• Zithrocare - (Khriz)
• Zithrocin - (Pharma Nutria)
• Zithromax - (Pfizer)
• Zithrozan - (Biopharma)
• Zit-Od - (PSA)
• Zmax - (Pfizer)

Poland

• Abiazyt - (Artespharm)
• Azibiot - (KRKA)
• Azigen - (Generics)
• Azimycin - (Polfa Tarchomin)
• AziTeva - (Teva)
• Azitrin - (Genexo)
• AzitroLEK - (Sandoz)
• Azitro-Mepha - (Mepha)
• Azitrox - (Zentiva)
• Azycyna - (Adamed)
• Azytact - (Tactica)
• Azyter - (Thea)
• Bactrazol - (Teva)
• Canbiox - (Apothez)
• Macromax - (PharmaSwiss)
• Nobaxin - (Lek-Am)
• Oranex - (Farmacom)
• Sumamed - (Teva)
• Zetamax - (Pfizer)

Portugal

• 3Z - (Jaba Recordati)
• Arzomicina - (APS)
• Azimax - (Pfizer)
• Azimed - (Daquimed)
• Aziton - (Labesfal)
• Azitrix - (Pentafarma)
• Azixratio - (Ratiopharm)
• Azyter - (Thea)
• Biozitra - (BioSaude)
• Gigatrom - (Medilusa)
• Imrotim - (Statim)
• Lazitrom - (Azevedos)
• Neofarmiz - (Farmoz)
• Unizitro - (Tecnimede)
- Vascin - (Helm)
- Zithromax - (Pfizer)
- Zitrina - (Decomed)
- Zitrozina - (Sidefarma)

**Russian Federation**
- Azicid - (Zentiva)
- Azimycin - (Micro)
- Azithrox - (Farmstandart)
- Azithrus - (Sintez)
- Azitral - (Shreya)
- Aziwok - (Wockhardt)
- Azydrop - (Thea)
- Ecomed - (Avva)
- Hemomycin - (Hemofarm)
- Safocid - (Stada)
- Sumaklid - (Biosinteze)
- Sumamecin - (Obolenskoe)
- Sumamed - (Pliva)
- Sumamox - (Oxford Laboratories)
- Sumatrolid - (Ozone)
- Sumazid - (Bryntsalov)
- Tremak - (Sanovel)
- Zetamax - (Pfizer)
- ZI-Factor - (Veropharm)
- Zithrocin - (Unique)
- Zitnob - (Nobel)
- Zitrolid - (Valenta)

**Singapore**
- Azimax - (Hovid)
- AZmycin - (Invent)
- Binozyt - (Sandoz)
- Zithromax - (Pfizer)
- Zmax - (Pfizer)

**South Africa**
- Azimax - (Teva)
- Binozyt - (Zydus)
- Clamelle - (Cipla-Medpro)
- Jubazi - (LeBasi)
- Ultreon - (Pfizer)
- Varimax - (MDI)
- Zeemide - (Ascendis)
- Zithrogen - (Mylan)
- Zithromax - (Pfizer)

**Spain**
- Altezym - (Alter)
- Aratro - (Arafarma)
- Azydrop - (Thea)
- Goxil - (Pfizer)
- Pefloden - (Vita)
- Toraseptol - (Warner Chilcott)
- Vinzam - (Almirall)
- Zentavion - (Warner Chilcott)
- Zitromax - (Pfizer)

Sweden

- Azitromax - (Pfizer)
- Azyter - (Thea)

Switzerland

- Azitro - (Acino)
- Zithromax - (Pfizer)

Thailand

- Azith - (Siam Bheasach)
- Azithrin - (TO-Chemicals)
- Azithro - (M & H)
- Azycin - (GPO)
- Azyter - (Thea)
- Binozyt - (Sandoz)
- Floctil - (Unison)
- Meithromax - (Meiji)
- Onzet - (M & H)
- Zithromax - (Pfizer)
- Zmax - (Pfizer)

Turkey

- Azacid - (Fako)
- Azax - (Nobel)
- Azeltin - (Biofarma)
- Azitro - (Deva)
- Azitrotek - (Deva)
- Azomax - (Kocak)
- Azro - (Zentiva)
- Azyter - (Thea)
- Tremac - (Sanovel)
- Zitromax - (Pfizer)
- Zitrotek - (Pfizer)

Ukraine

- Azax - (Nobel)
- Azibiot - (KRKA)
- Azicin - (Darnitsa)
- Azimed - (Arterium)
- Azinort - (Norton)
- Azithral - (Alembic)
- Azithro - (Sandoz)
- Azithromax - (Pharmascience)
- Azitrox - (Zentiva)
- Aziwok - (Wockhardt)
- Azo - (Tulip)
- Azro - (Eczacibasi)
- Hemomicin - (Hemofarm)
- Ormax - (Sperko)
- Sumamed - (Teva)
- Zatrin - (Euro Lifecare)
- Zetamax - (Pfizer)
- Ziromin - (World Medicine)
- Zithrocin - (Unique)
- Zithrolex - (October Pharma)
- Zomax - (Hikma)
- Zyomicin - (Kusum)

United Arab Emirates
- Azomycin - (Julphar)

United Kingdom
- Azyter - (Spectrum)
- Clamelle - (Actavis)
- Zedbac - (Aspire)
- Zithromax - (Pfizer)

Venezuela
- Amizin - (Giempii)
- Amovin - (Cofasa)
- Aruzilina - (Leti)
- Arzomidol - (Dollder)
- Atromizin - (Cafar)
- Azigram - (Vivax)
- Azimakrol - (Roemmers-Klinos)
- Azitrom - (SM)
- Azitromin - (Farma)
- Binozyt - (Sandoz)
- Ricilina - (Gynopharm)
- Saver - (Elmor)
- Surgot - (Klinos)
- Tromizid - (Medley)
- Zitromax - (Pfizer)
- Zival - (Valmor)
- Zocin - (Biogalenic)